
Drug Discovery and Evaluation: Pharmacological Assays

H. Gerhard Vogel (Ed.)

Drug Discovery and Evaluation: Pharmacological Assays

Third Completely Revised, Updated and Enlarged Edition

With 5 Figures and 66 Tables

 Springer

Hans Gerhard Vogel
Bohl Str. 28
73430 Aalen
Germany

ISBN: 978-3-540-70995-4

This publication is available also as:
Print publication under ISBN 978-3-540-71420-0 and
Print and electronic bundle under ISBN 978-3-540-71419-4

Library of Congress Control Number: 2007936031

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

Springer is part of Springer Science+Business Media

springer.com

© Springer-Verlag Berlin Heidelberg New York 2008

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about the application of operative techniques and medications contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Printed on acid-free paper

SPIN: 11733775 2109 - 5 4 3 2 1 0

Preface to the Third Edition

The third edition of the book *Drug Discovery and Evaluation. Pharmacological Assays* is presented here.

The volume of data has risen considerably compared to the second edition. In particular, a large number of assays have been added. Meanwhile, data on Safety Pharmacology have been removed from this edition. An extended discussion of that important aspect of pharmacology was published in the book *Drug Discovery and Evaluation. Safety and Pharmacokinetic Assays*, edited by H. G. Vogel, F. J. Hock, J. Maas, and D. Mayer, by Springer in 2006.

Several of my colleagues provided essential contributions to this edition. In particular I am indebted to S. A. Mousa for rewriting the chapter Pharmacological Assays in Thrombosis and Hemostasis, S. G. E. Hart, for rewriting the chapter Activity on Urinary Tract, G. Müller for rewriting and amending the chapter Antidiabetic Activity, B. Schultz for amending the chapter Ophthalmologic Activity, and J. Sandow for rewriting the chapter Endocrinology. All chapters have been revised and thoroughly updated as well.

The approach to drug discovery is changing continuously. Decades ago, many drugs were found by serendipity in clinical trials. Most new drugs, however, were found by the classical approach in animal experiments. This approach has the advantage of relatively high predictability, but it also has the disadvantage that little information is provided about the molecular mechanisms involved in the observed effects, and the detection of drugs with new mechanisms always required new models.

It is generally believed that the costs of developing new pharmaceutical drugs are exploding, while the output of new drugs is actually decreasing. A change in paradigm, the *target-based or mechanism-based drug discovery approach*, was therefore welcomed with great enthusiasm. The techniques of combinatorial chemistry could generate thousands of compounds to be tested against thousands of targets using high-throughput and ultra-high-throughput technology with tremendous capacity. This made it highly effective for the identification of target-selective compounds. However, despite the fact that this approach is very advantageous from a scientific and practical viewpoint, it did not translate into a high success rate in the discovery of new drugs. This has naturally led to questions regarding the success of target-based drug discovery and, more importantly, a search for alternatives.

The target-based approach has therefore been replaced again by the *physiology-based approach*, the classical drug discovery paradigm, or the *function-based approach*, which seeks to induce a therapeutic effect by normalizing a disease-specific abnormality.

On top of this, important changes in the management of some of the larger drug companies have taken place in recent years. Modern managers were installed as chief executive officers and other high-level executives, quite often with little or no biological and technical experience. They were more interested in blockbusters

and in shareholders' value than finding new drugs, especially for rare diseases. Research workers were confronted with cumbersome and inflexible organizational structures characterized by regimentation, control, conformity, and excessive bureaucracy. Consequently, creativity and productivity decreased in this environment. Recently, however, there are signs that the situation is changing.

In this book we ask the question: "Quo vadis, pharmacology?" We suggest giving pharmacologists the freedom, time, and money to carry out their own ideas. We also describe animal models of rare diseases that enable the medically trained pharmacologist to find appropriate drugs.

We are well aware that the rapid progress in biology will once again change the methodological approach in the coming years, and that electronic media will continuously help the researcher to access and share information. However, it is becoming more and more evident that many young pharmacologists have only limited training in classical pharmacological methodologies. When searching for these methods, researchers will only find insufficient information on the methodological details in the electronic databases currently available. To this end, we hope the current book may bridge this gap by comprehensively covering those pharmacological methods utilized for over more than a hundred years.

At this point I would like to express my sincere thanks to all colleagues who contributed to the new and to the earlier editions of this book. Their names and affiliations are given in alphabetical order.

Spring 2007

H. Gerhard Vogel

Preface to the Second Edition

The first edition of “Drug Discovery and Evaluation – Pharmacological Assays” has been well accepted by a broad readership ranging from experienced pharmacologists to students of pharmacology. Therefore, already after a short period of time the question for a second edition arose.

The first edition was mainly centered around the personal laboratory experience of the editors and the contributors. The second edition tries to close evident gaps. The input of biochemistry to pharmacology has grown. Molecular pharmacology puts more emphasis on the mode of action of drugs, albeit it becomes clear that the activities of most drugs are not confined to one single mode of action. Studies in single cells become more and more popular, however, they do not cover the complexity of a whole organism. Possible side effects of drugs can be better detected in whole animals than in single cells. Therefore, the new requirements of the health authorities on safety pharmacology put emphasis on experiments not only in whole anesthetized animals but in conscious ones. The second edition of this book takes note of these requirements and devotes special chapters for each indication to safety pharmacology.

Molecular biology also introduced new methods to pharmacology, such as the polymerase chain reaction (PCR), reverse PCR, Northern, Western and Southern blotting. Very recently, microarray technology, proteomics, and mass spectroscopy were added as novel *in vitro* methods. Furthermore, genetically modified animals have been created which resemble human diseases. Pharmacogenomics has already begun to influence pharmacology and even will have greater input in the future. Special attention is given to these new achievements in various chapters of the book.

The editor and the co-editors are well aware that the rapid progress in biology during the next decades will change the methodological approach. Electronic media will help the researcher for continuous information. However, it becomes more and more evident, that young pharmacologists have only insufficient training in the classical pharmacological methodology. Searching for these methods, e.g., for safety pharmacology, the researchers cannot find sufficient information on the methodological details in the electronic data bases currently available. This book covering the pharmacological methods of more than hundred years may be of help.

The guidelines concerning the care and use of laboratory animals have been updated.

A change in paradigm of pharmacological research has been claimed but superiorities of these new approaches compared to the old ones have still to be proven. To address this, an introductory chapter on new strategies in drug discovery and evaluation has been added, including combinatorial chemistry; high throughput screening, ultrahigh throughput screening and high content screening; pharmacogenomics, proteomics and array technology. Some critical thoughts on errors in screening procedures have been added.

At this place, we would like to express our sincere thanks to all colleagues who contributed to the new and to the first edition of this book. Their names and their positions are given alphabetically.

March 2002

H. Gerhard Vogel
Also in the name of the co-editors

Preface to the First Edition

This book is intended to be an aid for experienced pharmacologists as well as for newcomers in the field of experimental pharmacology. The student in pharmacology, the pharmacist and the medicinal chemist will find a survey of pharmacological assays that can be used for a given indication and for which methods have demonstrated their relevance. The researchers working in special fields of pharmacology will find assays in other, unfamiliar areas which might help to expand their own research.

Certain therapeutic domains, such as cardiovascular, respiratory and renal disorders, psychiatry and neurology, peripheral nerve function, pain and rheumatic diseases, metabolic and endocrine diseases including diseases of the gastrointestinal tract, are discussed in this book.

Each chapter is divided into pharmacological classes, e.g., anxiolytics, anti-epileptics, neuroleptics, antidepressants, or anti-Parkinson drugs. For each class, *in vitro* methods, tests on isolated organs and *in vivo* methods are described.

For each method the purpose and rationale are given first, followed by a description of the procedure, evaluation of the data, modifications of the method described in the literature, and the relevant references. If possible, a critical assessment of the method based on personal experience is added. The hints for modifications of the method and the extended reference list will be of value for the experienced pharmacologist.

A few words for the justification for a book of this kind: In 1959, A.J. Lehman, Director of the Division of Pharmacology at the Food and Drug Administration, USA, wrote:

... Pharmacologists are individualists. Like most scientists they are seldom willing to copy each other's techniques in detail, and so their methods vary from one to the other. Nevertheless, there are basic principles and techniques which must be applied to establish the safety of a new drug.

Visitors could also read a sticker in his office:

You too can learn pharmacology, in only three lessons: each of them lasting ten years.

Pharmacologists have always used methods from neighboring disciplines; in the past, e.g. from anatomy, pathology, surgery, zoology and predominantly physiology. Useful methods also came from electrophysiology and the behavioral sciences. Earlier drug discovery was almost exclusively based on animal experiments, clinical observations and serendipity.

In recent years, a major input has come from biochemistry. The effect of many drugs in human therapy could be explained biochemically as effects on specific enzymes or receptors. With the detection of more and more receptor subtypes, the

activity spectrum of a single compound became more and more complicated. At present, molecular biology provides pharmacologists with human receptors and ion channels expressed in mammalian cells in culture. This avoids the apparently existing species differences, but the multitude of natural and perhaps artificial subtypes raises the question of physiological and pathological relevance.

The challenge for the pharmacologist always will be to correlate *in vitro* data with *in vivo* findings, bearing in mind the old saying: "*In vitro simplicitas, in vivo veritas*". The effects found in tissue cultures are quite often not typical for an intact organism.

Pharmacologists, especially in industry, have the task to find new drugs for human therapy by using appropriate models. Pharmacological models have to be relevant, that means they should predict the intended therapeutic indications. A pharmacological model can be considered relevant or correlational, if the effects obtained correlate with results observed in human therapy.

To be relevant or "correlational", a model has to fulfill some basic criteria:

- First, the model must be sensitive in a dose-dependent fashion to standard compounds that are known to possess the desired therapeutic property.
- Second, the relative potency of known active agents in the model should be comparable to their relative potency in clinical use.
- Third, the model should be selective, i.e. the effects of known agents in this therapeutic indication should be distinguishable from effects of drugs for other indications. Positive data with a new compound allow the prediction of a therapeutic effect in patients.

If new assays are applied to indications for which no effective drug is known, there must be sufficient evidence that this model is relevant for the pathological status in this indication.

The methods presented in this book have been selected according to these criteria.

Considerable discussion is going on about the necessity of animal experiments. One has to accept that only the whole animal can reflect the complexity of a human being. Even an experiment with human volunteers is only a model, albeit a highly relevant one, to investigate therapeutic effects in patients. The degree of relevance increases from isolated molecules (e.g. receptors or enzymes) to organelles, to organs up to conscious animals and human volunteers.

Without any doubt, animal experiments are necessary for the discovery and evaluation of drugs. However, they should be performed only if they are necessary and well conceived.

In Chapter N, regulations existing in various countries concerning the care and use of laboratory animals are listed. Furthermore, guidelines for anesthesia, blood collection and euthanasia in laboratory animals are given. In carrying out animal experiments, one must adhere strictly to these guidelines. Following these rules and planning the experiments well, will eliminate or minimize pain and discomfort to the animal. The methods described in this book had the welfare of the animals as well as the benefit of the procedure for the well-being of mankind in mind.

Here, we would like to express our sincere thanks to all colleagues who contributed to this book. Their names and positions are given alphabetically below.

Autumn 1996

*H. Gerhard Vogel,
Wolfgang H. Vogel*

Contents

Volume 1

Chapter 0

Introduction Strategies in Drug Discovery and Evaluation 1

0.1	Historical Approaches in Drug Discovery	1
0.2	Classical Pharmacological Approaches	3
0.3	Quo Vadis, Pharmacology?	5
0.3.1	Managers, Not Leaders	6
0.3.2	Pressures From Shareholders	6
0.3.3	Merger Mania	6
0.3.4	Blockbuster Mania	6
0.3.5	Orphan Drugs and Drug Pricing	6
0.4	New Approaches in Drug Discovery	9
0.4.1	Combinatorial Chemistry	9
0.4.2	High-Throughput Screening, Ultra-High-Throughput Screening, and High-Content Screening	11
0.4.2.1	Errors in HTS	13
0.4.2.2	Statistical Evaluation of HTS	13
0.4.3	Technologies for High-Throughput Screening	15
0.4.3.1	Dispensing Technologies	16
0.4.3.2	Cell-Based Assays	16
0.4.3.3	High-Throughput Assay Technologies for Ion Channels	17
0.4.3.4	Detection Methods	18
0.4.4	Pharmacogenomics	29
0.4.5	Proteomics	35
0.4.6	Array Technology	37
0.4.7	NMR Technology	41
0.5	Errors in Screening Procedures	44

Chapter A

Cardiovascular Activity 47

A.1	Cardiovascular Analysis	51
A.1.1	In Vitro Methods	51
A.1.1.1	α^1 -Adrenoreceptor Binding	51
A.1.1.2	α^2 -Adrenoreceptor Binding	54
A.1.1.3	Electrically Stimulated Release of [³ H]Norepinephrine from Brain Slices	57

A.1.1.4	Imidazoline Receptor Binding	59
A.1.1.5	β -Adrenoreceptor Binding	62
A.1.1.6	β^1 -Adrenoreceptor Binding	64
A.1.1.7	β^2 -Adrenoreceptor Binding	65
A.1.1.8	Adenosine A ¹ Receptor Binding	69
A.1.1.9	Adenosine A ₂ Receptor Binding	71
A.1.1.10	Adenosine A ³ Receptor Binding	73
A.1.1.11	Inhibition of Adenosine Uptake in Human Erythrocytes	74
A.1.1.12	Inhibition of Vasopeptidases	75
A.1.1.12.1	Inhibition of the Angiotensin-Converting Enzyme in Vitro Purpose and Rationale	76
A.1.1.12.2	Inhibition of Neutral Endopeptidase (Neprilysin)	77
A.1.1.13	Quantitative Autoradiographic Localization of Angiotensin- Converting Enzyme	79
A.1.1.14	Angiotensin Antagonism	80
A.1.1.14.1	Angiotensin II Receptor Binding	80
A.1.1.14.2	AT ² Receptor Binding	84
A.1.1.14.3	Angiotensin II Induced Contraction in Isolated Rabbit Aorta	85
A.1.1.14.4	Angiotensin II Antagonism in Vivo	86
A.1.1.15	Renin-Inhibitory Activity Using Human Kidney Renin and a Synthetic Substrate	88
A.1.1.16	PAF Binding Assay	90
A.1.1.17	Endothelin	91
A.1.1.17.1	General Considerations	91
A.1.1.17.2	Evaluation of Endothelin Activity	92
A.1.1.17.3	Endothelin Receptor Antagonism in Vitro	93
A.1.1.17.4	Endothelin Receptor Antagonism in Vivo	95
A.1.1.17.5	Quantitative Autoradiographic Localization of Endothelin-1 Receptor	97
A.1.1.17.6	Inhibition of Endothelin Converting Enzyme	98
A.1.1.18	Nitric Oxide	101
A.1.1.18.1	General Considerations on Nitric Oxide	101
A.1.1.18.2	Bioassay of EDRF Release	102
A.1.1.18.3	Isolated Arteries with and Without Endothelium	103
A.1.1.18.4	Nitric Oxide Formation by Cultured Endothelial Cells	104
A.1.1.18.5	Expression of Nitric Oxide Synthase	107
A.1.1.19	Inhibition of Rho Kinase	109
A.1.1.20	Inhibition of Na ⁺ /H ⁺ Exchange	109
A.1.1.20.1	Inhibition of Na ⁺ /H ⁺ Exchange in Thrombocytes	111
A.1.1.20.2	Inhibition of Na ⁺ /H ⁺ Exchange in Cholesterol Activated Rabbit Erythrocytes	111
A.1.1.20.3	Sodium Influx into Cultured Cardiac Myocytes	112
A.1.1.20.4	Inhibition of Na ⁺ /H ⁺ Exchange into Cultured Aortic Endothelial Cells	113
A.1.1.20.5	NHE Activity Measured by Intracellular pH in Isolated Ventricular Myocytes	113
A.1.1.20.6	NHE Subtype Specificity	114
A.1.1.21	Phosphodiesterases	115
A.1.1.21.1	Inhibition of Phosphodiesterase	116
A.1.1.22	Stimulation of Heart Membrane Adenylate Cyclase	121
A.1.1.23	³ H-Forskolin Binding Assay	123

A.1.1.24	Patch Clamp Technique	124
A.1.1.24.1	Patch Clamp Technique in Isolated Cardiac Myocytes	126
A.1.1.24.2	Voltage Clamp Studies on Sodium Channels	127
A.1.1.24.3	Voltage Clamp Studies on Potassium Channels	130
A.1.1.24.4	Voltage Clamp Studies on Calcium Channels	136
A.1.1.24.5	Patch Clamp Studies on Chloride Channels	138
A.1.1.25	Inhibition of Hyperpolarization-Activated Channels	139
A.1.1.26	Measurement of Cytosolic Calcium with Fluorescent Indicators	141
A.1.1.27	Measurement of Contractile Force of Isolated Cardiac Myocytes	142
A.1.1.28	Adrenomedullin	143
A.1.1.28.1	General Considerations	143
A.1.1.28.2	Receptor Binding of Adrenomedullin	146
A.1.1.29	Atrial Natriuretic Factor (ANF)	147
A.1.1.29.1	General Considerations	147
A.1.1.29.2	Bioassay for ANF	148
A.1.1.29.3	Receptor Binding of ANF	149
A.1.1.29.4	ANF Gene Expression	150
A.1.1.29.5	Radioimmunoassay for ANF	151
A.1.1.30	Urotensin II	152
A.1.1.30.1	General Considerations	152
A.1.1.30.2	Rat Thoracic Aorta Bioassay for Urotensin II	153
A.1.1.30.3	Intracellular Calcium Mobilization Assay	155
A.1.1.30.4	Receptor Binding of Urotensin II	156
A.1.1.30.5	Urotensin II Gene Expression	158
A.1.1.31	Apelin	160
A.1.1.31.1	General Considerations	160
A.1.1.31.2	Cardiovascular Actions of Apelin	161
A.1.1.32	TRP Channels	163
A.1.1.32.1	General Considerations	163
A.1.1.32.2	TRPC Channels	164
A.1.1.32.3	TRPM Channels	166
A.1.1.32.4	TRPV Channels	167
A.1.1.32.5	TRPV1 Receptor Assay	169
A.1.2	Studies in Isolated Organs	170
A.1.2.1	α -Sympatholytic Activity in Isolated Vascular Smooth Muscle	170
A.1.2.2	α -Sympatholytic Activity in the Isolated Guinea Pig Seminal Vesicle	171
A.1.2.3	α -Sympatholytic Activity in the Isolated Vas Deferens of the Rat	171
A.1.2.4	α -Sympatholytic Activity in the Isolated Rat Spleen	173
A.1.2.5	α -Sympatholytic Activity in the Isolated Rat Anococcygeus Muscle	174
A.1.2.6	β_1 -Sympatholytic Activity in Isolated Guinea Pig Atria	175
A.1.2.7	β_2 -Sympatholytic Activity in the Isolated Tracheal Chain	177
A.1.2.8	Angiotensin Converting Enzyme Inhibition in the Isolated Guinea Pig Ileum	178
A.1.2.9	Contractile and Relaxing Activity on Isolated Blood Vessels Including Effects of Potassium Channel Openers	179
A.1.2.10	Isolated Guinea Pig Ureter	183
A.1.2.11	Isolated Corpus Caverosum	184

A.1.3	Cardiovascular Analysis in Vivo	187
A.1.3.1	Hemodynamic Screening in Anesthetized Rats	187
A.1.3.2	Blood Pressure in Pithed Rats	189
A.1.3.3	Antihypertensive Vasodilator Activity in Ganglion-Blocked, Angiotensin II Supported Rats	191
A.1.3.4	Blood Pressure in Conscious Hypertensive Rats (Tail Cuff Method)	192
A.1.3.5	Direct Measurement of Blood Pressure in Conscious Rats with Indwelling Catheter	193
A.1.3.6	Cannulation Techniques in Rodents	195
A.1.3.6.1	Permanent Cannulation of the Jugular Vein in Rats	195
A.1.3.6.2	Permanent Cannulation of the Renal Vein in Rats	196
A.1.3.6.3	Permanent Cannulation of the Portal Vein in Rats	197
A.1.3.6.4	Permanent Cannulation of the Thoracic Duct in Rats	197
A.1.3.6.5	Portacaval Anastomosis in Rats	198
A.1.3.7	Cardiovascular Analysis in Anesthetized Mice	199
A.1.3.8	Blood Pressure in Anesthetized Cats	200
A.1.3.9	Cardiovascular Drug Challenging Experiments in Anesthetized Dogs	201
A.1.3.10	Hemodynamic Analysis in Anaesthetized Dogs	202
A.1.3.11	Hemodynamic Measurements in Conscious Dogs	204
A.1.3.12	Hemodynamic Studies in Monkeys	206
A.1.3.13	Measurement of Cardiac Output and Regional Blood Flow with Microspheres	206
A.1.3.14	Carotid Artery Loop Technique	207
A.1.3.15	Measurement of Heart Dimensions in Anesthetized Dogs	209
A.1.3.16	Telemetric Monitoring of Cardiovascular Parameters in Rats	210
A.1.3.17	Cardiovascular Effects After Intracerebroventricular Administration	212
A.1.3.18	Influence on Orthostatic Hypotension	213
A.1.3.19	Bezold-Jarisch Reflex	214
A.1.3.20	Endotoxin Induced Shock	216
A.1.3.21	Hemorrhagic Shock	218
A.1.3.22	Tourniquet Shock	219
A.1.3.23	Heat Stroke	220
A.1.3.24	α - and β -Adrenoreceptors in the Mouse Iris	221
A.1.3.25	α_2 -Adrenoreceptor Blockade Measured in Vivo by Clonidine-Induced Sleep in Chicks	223
A.1.3.26	Activity at β_1 - and β_2 -Adrenoreceptors in the Rat	223
A.1.3.27	β_1 - and β_2 -Sympatholytic Activity in Dogs	224
A.1.3.28	Intrinsic β -Sympathomimetic Activity in Reserpine-Pretreated Dogs	225
A.1.3.29	Cat Nictitating Membrane Preparation (Ganglion Blocking Activity)	226
A.1.3.30	Assessment of Ganglion-Blocking Activity in the Isolated Bovine Retractor Penis Muscle	228
A.1.3.31	Angiotensin II Antagonism	229
A.1.3.32	ACE Inhibition Measured in Vivo in the Rat	233
A.1.3.33	Evaluation of Renin Inhibitors in Dogs	234
A.1.3.34	Evaluation of Renin Inhibitors in Monkeys	235
A.1.3.35	Penile Erection in Rabbits	237
A.1.4	Cardiovascular Safety Studies	238

A.2	Methods to Induce Experimental Hypertension	239
A.2.0.1	Acute Renal Hypertension in Rats	239
A.2.0.2	Chronic Renal Hypertension in Rats	239
A.2.0.3	Chronic Renal Hypertension in Dogs	240
A.2.0.4	Neurogenic Hypertension in Dogs	241
A.2.0.5	DOCA-salt Induced Hypertension in Rats	242
A.2.0.6	Fructose Induced Hypertension in Rats	243
A.2.0.7	Genetic Hypertension in Rats	244
A.2.0.8	Hypertension Induced by Chronic NO-Synthase Inhibition	246
A.2.0.9	Pulmonary Hypertension Induced by Monocrotaline	247
A.2.0.10	Portal Hypertension in Rats	249
A.3	Coronary (Cardiac) Drugs	251
A.3.1	Isolated Organs	251
A.3.1.1	Heart-Lung Preparation	251
A.3.1.2	Isolated Heart According to Langendorff	253
A.3.1.3	Coronary Artery Ligation in Isolated Working Rat Heart	259
A.3.1.4	Isolated Working Heart Model in Infarcted Rat Heart	261
A.3.1.5	Relaxation of Bovine Coronary Artery	262
A.3.2	In Vivo Methods	263
A.3.2.1	Isoproterenol Induced Myocardial Necrosis in Rats	263
A.3.2.2	Myocardial Infarction After Coronary Ligation in Rodents	264
A.3.2.3	Occlusion of Coronary Artery in Anesthetized Dogs and Pigs	269
A.3.2.4	Acute Ischemia by Injection of Microspheres in Dogs	271
A.3.2.5	Influence on Myocardial Preconditioning	273
A.3.2.6	MRI Studies of Cardiac Function	276
A.3.2.7	MRI Studies After Heart and Lung Transplantation	277
A.3.3	Ex Vivo Methods	279
A.3.3.1	Plastic Casts from Coronary Vasculature Bed	279
A.4	Calcium Uptake Inhibiting Activity	280
A.4.0.1	General Considerations	280
A.4.1	In Vitro Methods	282
A.4.1.1	³ H-Nitrendipine Binding in Vitro	282
A.4.2	Calcium Antagonism in Isolated Organs	286
A.4.2.1	Calcium Antagonism on Action Potential of Isolated Guinea Pig Papillary Muscle	286
A.4.2.2	Calcium Antagonism in the Isolated Guinea Pig Atrium	286
A.4.2.3	Calcium Antagonism in the Isolated Rabbit Aorta	287
A.4.2.4	Calcium Antagonism in the Isolated Guinea Pig Pulmonary Artery	288
A.4.3	In Vivo Methods	289
A.4.3.1	Evaluation of Calcium Blockers in the Pithed Rat	289
A.5	Anti-Arrhythmic Activity	290
A.5.0.1	General Considerations	290
A.5.0.2	Electrocardiography in Animals	292
A.5.0.3	Aconitine Antagonism in Rats	293
A.5.0.4	Digoxin-Induced Ventricular Arrhythmias in Anesthetized Guinea Pigs	295
A.5.0.5	Strophanthin or Ouabain Induced Arrhythmia	296
A.5.0.6	Ventricular Fibrillation Electrical Threshold	297
A.5.0.7	Coronary Artery Ligation, Reperfusion Arrhythmia and Infarct Size in Rats	298

A.5.0.8	Ventricular Arrhythmia After Coronary Occlusion	301
A.5.0.8.1	Ventricular Fibrillation After Coronary Occlusion and Reperfusion in Anesthetized Dogs	301
A.5.0.8.2	Harris Dog Model of Ventricular Tachycardia	303
A.5.0.8.3	Protection against Sudden Coronary Death	304
A.5.0.8.4	Ventricular Fibrillation Induced by Cardiac Ischemia During Exercise	306
A.5.0.9	Experimental Atrial Fibrillation	308
A.5.0.9.1	Atrial Fibrillation by Atrial Pacing in Dogs	308
A.5.0.9.2	Atrial Fibrillation in Chronically Instrumented Goats	309
A.5.0.9.3	Influence on Ultrarapid Delayed Rectifier Potassium Current in Pigs	311
A.5.0.10	Characterization of Anti-Arrhythmic Activity in the Isolated Right Ventricular Guinea Pig Papillary Muscle	312
A.5.0.11	Action Potential and Refractory Period in Isolated Left Ventricular Guinea Pig Papillary Muscle	314
A.6	Methods to Induce Cardiac Hypertrophy and Insufficiency	316
A.6.0.1	Cardiac Hypertrophy and Insufficiency in Rats	316
A.6.0.1.1	Aortic Banding in Rats	316
A.6.0.1.2	Chronic Heart Failure in Rats	318
A.6.0.2	Cardiac Hypertrophy and Insufficiency in Mice	321
A.6.0.2.1	Cardiac Hypertrophy in Mice	321
A.6.0.2.2	Chronic Heart Failure in Mice	322
A.6.0.2.3	Transgenic Mice and Heart Failure	323
A.6.0.3	Cardiac Insufficiency in Guinea Pigs	324
A.6.0.4	Cardiomyopathic Syrian Hamster	325
A.6.0.5	Cardiac Failure in Rabbits	327
A.6.0.6	Congestive Heart Failure in Dogs	329
A.6.0.7	Cardiac Failure in Pigs	332
A.6.0.8	Cardiac Failure in Sheep	335
A.6.0.9	Cardiac Failure in Monkeys	337
A.6.0.10	Cardiac Failure in Other Species	338
A.6.0.11	Hypertrophy of Cultured Cardiac Cells	339
A.7	Positive Inotropic Activity (Cardiac Glycosides)	340
A.7.0.1	General Considerations	340
A.7.1	In Vitro Tests	341
A.7.1.1	Ouabain Binding	341
A.7.1.2	Influence on Na ⁺ /K ⁺ ATPase	341
A.7.2	Tests in Isolated Tissues and Organs	343
A.7.2.1	Isolated Cat Papillary Muscle	343
A.7.2.2	Isolated Hamster Cardiomyopathic Heart	344
A.7.2.3	Potassium Loss from the Isolated Guinea Pig Heart	345
A.7.3	In Vivo Tests	345
A.7.3.1	Cardiac Toxicity in Cats (Hatcher's Method)	345
A.7.3.2	Decay Rate and Enteral Absorption Rate of Cardiac Glycosides	346
A.8	Effects on Blood Supply and on Arterial and Venous Tonus	347
A.8.1	Models for Stroke and Multi-Infarct Cerebral Dysfunction	347
A.8.1.1	Cerebral Ischemia by Carotid Artery Occlusion in Mongolian Gerbils	347
A.8.1.2	Forebrain Ischemia in Rats	349
A.8.1.3	Hypoxia Tolerance Test in Rats	350

A.8.1.4	Middle Cerebral Artery Occlusion in Rats	351
A.8.1.5	Photochemically Induced Focal Cerebral Ischemia in Rats . .	353
A.8.1.6	Microdialysis and Neuroprotection Experiments After Global Ischemia in Rats	355
A.8.1.7	Hypoxia/Hypoglycemia in Hippocampal Slices	356
A.8.1.8	Measurement of Local Cerebral Blood Flow and Glucose Utilization in Rats	356
A.8.1.9	Cerebrovascular Resistance in Anesthetized Baboons	358
A.8.1.10	Effect on Cerebral Blood Flow in Cats (Fluorography)	360
A.8.1.11	Effect on Cerebral Blood Flow and in Ischemic Skeletal Muscle in Rats (Laser-Doppler-Effect)	361
A.8.1.12	Traumatic Brain Injury	362
A.8.1.13	Cerebral Blood Flow Measured by NMRI	365
A.8.2	Peripheral Blood Supply	367
A.8.2.1	Perfused Hindquarter Preparation with Sympathetic Nerve Stimulation in Rats	367
A.8.2.2	Effect on Peripheral Blood Flow in Rats	369
A.8.2.3	Effect on Peripheral Blood Flow in Anesthetized Dogs	370
A.8.2.4	Effect on Peripheral Blood Supply Measured by Local Oxygen Pressure	372
A.8.2.5	Effect on Mesenteric Blood Flow in Rats	372
A.8.2.6	Effect on Pulmonary Blood Flow	374
A.8.2.7	Effect on Contractile Force of Ischemic Muscle	375
A.8.2.8	Effect on Perfusion of Rabbit Ear (Pissemiski Method)	376
A.8.2.9	Effect on Venous Tonus In Situ in Dogs	378
A.8.3	Arterial Aneurysms	379
A.8.3.1	General Considerations	379
A.8.3.2	Angiotensin II-Induced Aortic Aneurysm in Mice	380
A.8.4	Angiogenesis and Anti-Angiogenesis	382
A.8.4.1	General Considerations	382
A.8.4.2	Endothelial Cell Proliferation	383
A.8.4.3	Chorioallantoic Membrane Assay	384
A.8.4.4	Cornea Neovascularization	385
A.8.4.5	Rat Subcutaneous Air Sac Model	387
A.8.4.6	Mesenteric Window Angiogenesis Model	388
A.8.4.7	Quantification of Vascular Endothelial Growth Factor-C	388
A.8.4.8	Inhibitors of Vascular Endothelial Growth Factor	389

Chapter B

Pharmacological Assays in Thrombosis and Haemostasis 393

B.1	General Introduction	394
B.2	In Vitro Tests	394
B.2.1	Blood Coagulation Tests	394
B.2.2	Thrombelastography	395
B.2.3	Chandler Loop	396
B.2.4	Platelet Aggregation and Deaggregation in Platelet-Rich Plasma or Washed Platelets (Born Method) . .	397
B.2.5	Platelet Aggregation After Gel Filtration (Gel-Filtered Platelets, GFP)	400
B.2.6	Platelet Aggregation in Whole Blood	401

B.2.7	Platelet Micro- and Macro- Aggregation Using Laser Scattering	402
B.2.8	Fibrinogen Receptor Binding	403
B.2.9	Euglobulin Clot Lysis Time	405
B.2.10	Flow Behavior of Erythrocytes	405
B.2.11	Filterability of Erythrocytes	406
B.2.12	Erythrocyte Aggregation	407
B.2.13	Determination of Plasma Viscosity	408
B.3	In Vitro Models of Thrombosis	408
B.3.1	Cone-and-Plate Viscometry Under Shear-Flow Cytometry	410
B.3.2	Platelet Adhesion and Aggregation Under Dynamic Shear	412
B.3.3	Cell Adhesion to Immobilized Platelets: Parallel-Plate Flow Chamber	413
B.4	In Vivo or Ex Vivo Models	415
B.4.1	Stenosis- and Mechanical Injury-Induced Coronary Thrombosis: Folts Model	417
B.4.2	Stenosis- and Mechanical Injury- Induced Arterial and Venous Thrombosis: Harbauer-Model	421
B.4.3	Electrical-Induced Thrombosis	423
B.4.4	FeCl ₃ -Induced Thrombosis	424
B.4.5	Thrombin-Induced Clot Formation in Canine Coronary Artery	425
B.4.6	Laser-Induced Thrombosis	426
B.4.7	Photochemical-Induced Thrombosis	427
B.4.8	Foreign-Surface-Induced Thrombosis	428
B.4.8.1	Wire Coil-Induced Thrombosis	428
B.4.8.2	Eversion Graft-Induced Thrombosis	429
B.4.8.3	Arteriovenous Shunt Thrombosis	430
B.4.8.4	Thread-Induced Venous Thrombosis	431
B.4.8.5	Thrombus Formation on Superfused Tendon	432
B.4.9	Stasis-Induced Thrombosis (Wessler Model)	432
B.4.10	Disseminated Intravascular Coagulation (DIC) Model	434
B.4.11	Microvascular Thrombosis in Trauma Models	434
B.4.12	Cardiopulmonary Bypass Models	434
B.4.13	Extracorporeal Thrombosis Models	435
B.4.14	Experimental Thrombocytopenia or Leucocytopenia	436
B.4.15	Collagenase-Induced Thrombocytopenia	437
B.4.16	Reversible Intravital Aggregation of Platelets	437
B.5	Bleeding Models	438
B.5.1	Subaqueous Tail Bleeding Time in Rodents	438
B.5.2	Arterial Bleeding Time in Mesentery	439
B.5.3	Template Bleeding Time Method	439
B.6	Genetic Models of Hemostasis and Thrombosis	440
B.6.1	Knock-Out Mice	443
B.7	Critical Issues in Experimental Models	451
B.7.1	The Use of Positive Control	451
B.7.2	Evaluation of Bleeding Tendency	451
B.7.3	Selection of Models Based on Species-Dependent Pharmacology/Physiology	452
B.7.4	Selection of Models Based on Pharmacokinetics	453
B.7.5	Clinical Relevance of Data Derived from Experimental Models	453
B.8	Safety Assays in Thrombosis and Haemostasis	455

Chapter C		
Activity on Urinary Tract		457
C.1	Diuretic and Saluretic Activity	458
C.1.1	In Vitro Methods	458
C.1.1.1	Carbonic Anhydrase Inhibition In Vitro	458
C.1.2	In Vivo Methods	459
C.1.2.1	Diuretic Activity in Rats (LIPSCHITZ Test)	459
C.1.2.2	Saluretic Activity in Rats	461
C.1.2.3	Diuretic and Saluretic Activity in Dogs	461
C.2	Assessment of Renal Function	462
C.2.1	In Vitro Methods	462
C.2.1.1	Patch Clamp Technique in Kidney Cells	462
C.2.1.2	Perfusion of Isolated Kidney Tubules	463
C.2.1.3	Isolated Perfused Kidney	466
C.2.2	In Vivo Methods	467
C.2.2.1	Clearance Methods	467
C.2.2.2	Assessment of Glomerular Filtration Rate (GFR) and Renal Blood Flow (RBF)	469
C.2.2.2.1	Assessment of GFR by Plasma Chemistry	469
C.2.2.2.2	Assessment of RBF by Intra-vascular Doppler Flow Probes	472
C.2.2.2.3	Assessment of GFR and RBF by Scintigraphic Imaging	473
C.2.2.3	Assessment of Renal Tubule Functions	474
C.2.2.3.1	Urinalysis	474
C.2.2.3.2	Electrolyte Excretion	477
C.2.2.3.3	Fractional Excretion Methods	477
C.2.2.3.4	Quantitative Electrolyte Excretion	479
C.2.2.3.5	Assessment of Tubular Transport Processes using Transport Substrates and Inhibitors	480
C.2.2.4	Assessment of Renal Concentrating Ability	481
C.2.2.4.1	Solute-Free Water Excretion and Reabsorption	481
C.2.2.4.2	Assessment of Medullary Osmolarity and Blood Flow	482
C.2.2.5	Micropuncture Techniques in the Rat	483
C.2.2.6	Stop-Flow Technique	485
C.3	Impaired Renal Function	485
C.3.1	Chronic Renal Failure in the Rat	485
C.3.2	Chronic Renal Failure After Subtotal (Five-Sixths) Nephrectomy in Rats	487
C.3.3	Experimental Nephritis	490
C.3.3.1	General Considerations	490
C.3.3.2	Nephrotoxic Serum Nephritis	490
C.3.4	Experimental Nephrosis	493
C.4	Uricosuric and Hypo-Uricemic Activity	495
C.4.1	In Vitro Methods	495
C.4.1.1	Inhibition of Xanthine Oxidase In Vitro Indicating Hypouricemic Activity	495
C.4.1.2	Urate Uptake in Brush Border Membrane Vesicles	495
C.4.2	In Vivo Methods	496
C.4.2.1	Diuretic and Uricosuric Activity in Mice	496
C.4.2.2	Hypouricemic Activity After Allantoxanamide Treatment in Rats	497

C.4.2.3	Hypouricemic and Uricosuric Activity After Potassium Oxonate Treatment in Rats	497
C.4.2.4	Phenol Red Excretion in Rats	498
C.4.2.5	Uricosuric Activity in Dalmatian Dogs	498
C.4.2.6	Uricosuric Activity in Cebus Monkeys	499
C.5	Influence on Lower Urinary Tract	500
C.5.1	In Vivo Studies	500
C.5.1.1	Micturition Studies	500
C.5.2	Studies in Isolated Organs	502
C.5.2.1	Studies on Renal Pelvis	502
C.5.2.2	Propagation of Impulses in the Guinea Pig Ureter	504
C.5.2.3	Studies on Urinary Bladder and Internal Urethral Sphincter	505
C.5.2.4	Effects on Isolated Urethra	508
C.5.2.5	Effects on External Urethral Sphincter	510

Chapter D

Respiratory Activity 511

D.1	In Vitro Tests	511
D.1.0.1	Histamine (H ₁) Receptor Binding	511
D.1.0.2	Muscarinic Receptor Binding	512
D.2	Effects on Air Ways	514
D.2.1	Tests in Isolated Organs	514
D.2.1.1	Spasmolytic Activity in Isolated Guinea Pig Lung Strips	514
D.2.1.2	Spasmolytic Activity in Isolated Trachea	515
D.2.1.3	Reactivity of the Isolated Perfused Trachea	518
D.2.1.4	Bronchial Perfusion of Isolated Lung	519
D.2.1.5	Vascular and Airway Responses in the Isolated Lung	520
D.2.2	In Vivo Tests	522
D.2.2.1	Bronchospasmolytic Activity in Anesthetized Guinea Pigs (Konzett-Rössler method)	522
D.2.2.2	Effect of Arachidonic Acid or PAF on Respiratory Function In Vivo	524
D.2.2.3	Bronchial Hyperreactivity	525
D.2.2.4	Body Plethysmography and Respiratory Parameters After Histamine- Induced Bronchoconstriction in Anesthetized Guinea Pigs	528
D.2.2.5	Pneumotachography in Anesthetized Guinea Pigs	530
D.2.2.6	Airway Microvascular Leakage	532
D.2.2.7	Isolated Larynx In Situ	533
D.2.2.8	Animal Models of Asthma	534
D.2.2.8.1	Treatment of Asthma	534
D.2.2.8.2	Prevention of Allergic Asthma Reaction	539
D.2.2.9	Bleomycin-Induced Pulmonary Fibrosis	541
D.2.2.10	Influence of Cytokines on Lung Fibrosis	544
D.2.2.11	Emphysema Models	547
D.2.2.12	Models of Chronic Obstructive Pulmonary Disease (COPD)	549
D.3	Antitussive Activity	551
D.3.0.1	Antitussive Activity After Irritant Inhalation in Guinea Pig	551
D.3.0.2	Cough Induced by Mechanical Stimulation	553
D.3.0.3	Cough Induced by Stimulation of the Nervus Laryngicus Superior	554

D.4	Effects on Tracheal Cells and Bronchial Mucus Secretion and Transport	555
D.4.0.1	In Vitro Studies of Mucus Secretion	555
D.4.0.2	Acute Studies of Mucus Secretion	556
D.4.0.3	Studies of Mucus Secretion With Chronic Cannulation	557
D.4.0.4	Bronchoalveolar Lavage	558
D.4.0.5	Ciliary Activity	559
D.4.0.6	Studies of Mucociliary Transport	561
D.4.0.7	Culture of Tracheal Epithelial Cells	562
D.4.0.8	Alveolar Macrophages	563
D.5	Safety Pharmacology of the Respiratory System	564

Chapter E
Psychotropic and Neurotropic Activity **565**

E.1	Effects on Behavior and Muscle Coordination	569
E.1.1	Spontaneous Behavior	569
E.1.1.1	General Considerations	569
E.1.1.2	Observational Assessment	569
E.1.1.3	Safety Pharmacology Core Battery	571
E.1.2	Effects on Motility (Sedative or Stimulatory Activity)	571
E.1.2.1	General Considerations	571
E.1.2.2	Method of Intermittent Observations	572
E.1.2.3	Open Field Test	573
E.1.2.4	Hole-Board Test	576
E.1.2.5	Combined Open Field Test	576
E.1.2.6	EEG Analysis From Rat Brain by Telemetry	577
E.1.3	Tests for Muscle Coordination	578
E.1.3.1	Inclined Plane	578
E.1.3.2	Chimney Test	579
E.1.3.3	Grip Strength	579
E.1.3.4	Rotarod Method	580
E.1.3.5	Treadmill Performance	581
E.1.3.6	Influence on Polysynaptic Reflexes	583
E.1.3.7	Masticatory Muscle Reflexes	584
E.2	Tests for Anxiolytic Activity	585
E.2.0.1	General Considerations	585
E.2.1	In Vitro Methods	586
E.2.1.1	GABA Receptor Binding	586
E.2.1.1.1	General Considerations	586
E.2.1.1.2	In Vitro Assay for GABAergic Compounds: [³ H]-GABA Receptor Binding	587
E.2.1.1.3	GABA _A Receptor Binding	589
E.2.1.1.4	GABA _B Receptor Binding	592
E.2.1.2	Benzodiazepine Receptor: [³ H]-Flunitrazepam Binding Assay	594
E.2.1.3	Serotonin Receptor Binding	596
E.2.1.3.1	General Considerations	596
E.2.1.3.2	Serotonin (5-HT _{1A}) Receptor: Binding of [³ H]-8-Hydroxy-2-(di-n-Propylamino)-Tetralin ([³ H]-DPAT)	602
E.2.1.3.3	Serotonin (5-HT _{1B}) Receptors in Brain: Binding of [³ H]5-Hydroxytryptamine ([³ H]5-HT)	607

E.2.1.3.4	5-HT ₃ Receptor in Rat Entorhinal Cortex Membranes: Binding of [³ H]GR 65630	609
E.2.1.4	Histamine H ₃ Receptor Binding in Brain	612
E.2.2	Anticonvulsant Activity	613
E.2.2.1	Pentylentetrazole (Metrazol) Induced Convulsions	613
E.2.2.2	Strychnine-Induced Convulsions	614
E.2.2.3	Picrotoxin-Induced Convulsions	615
E.2.2.4	Isoniazid-Induced Convulsions	615
E.2.2.5	Yohimbine-Induced Convulsions	616
E.2.3	Anti-Aggressive Activity	616
E.2.3.1	Foot-Shock-Induced Aggression	616
E.2.3.2	Isolation-Induced Aggression	617
E.2.3.3	Resident-Intruder Aggression Test	619
E.2.3.4	Water Competition Test	619
E.2.3.5	Maternal Aggression in Rats	620
E.2.3.6	Rage Reaction in Cats	621
E.2.4	Effects on Behavior	622
E.2.4.1	Anti-Anxiety Test (Light-Dark Model)	622
E.2.4.2	Anticipatory Anxiety in Mice	623
E.2.4.3	Social Interaction in Rats	624
E.2.4.4	Elevated Plus Maze Test	626
E.2.4.5	Water Maze Test	628
E.2.4.6	Staircase Test	629
E.2.4.7	Cork Gnawing Test in the Rat	630
E.2.4.8	Distress Vocalization in Rat Pups	630
E.2.4.9	Schedule Induced Polydipsia in Rats	631
E.2.4.10	Four Plate Test in Mice	632
E.2.4.11	Foot-shock-Induced Freezing Behavior in Rats	633
E.2.4.12	Experimental Anxiety in Mice	634
E.2.4.13	mCPP-Induced Anxiety in Rats	634
E.2.4.14	Acoustic Startle Response in Rats	636
E.2.4.15	Unconditioned Conflict Procedure (Vogel Test)	637
E.2.4.16	Novelty-Suppressed Feeding	638
E.2.4.17	Shock Probe Conflict Procedure	639
E.2.4.18	Ultrasound Induced Defensive Behavior in Rats	639
E.2.4.19	Anxiety/Defense Test Battery in Rats	640
E.2.4.20	Repetitive Transcranial Magnetic Stimulation	641
E.2.4.21	Marmoset Human Threat Test	642
E.2.4.22	Psychosocial Stress in Tree Shrews	643
E.2.4.23	Aversive Brain Stimulation	644
E.2.5	Conditioned Behavioral Responses	646
E.2.5.1	Sidman Avoidance Paradigm	646
E.2.5.2	Geller Conflict Paradigm	647
E.2.5.3	Progressive Ratio Procedure	650
E.2.5.4	Conditioned Defensive Burying in Rats	651
E.2.5.5	Taste Aversion Paradigm	652
E.2.5.6	Cued and Contextual Fear Conditioning	654
E.2.6	Effects on the Endocrine System	657
E.2.6.1	Plasma Catecholamine Levels During and After Stress	657
E.2.6.2	Plasma Corticosterone Levels Influenced by Psychotropic Drugs	658

E.2.7	Benzodiazepine Dependence	659
E.2.7.1	General Considerations	659
E.2.7.2	Benzodiazepine Tolerance and Dependence in Rats	659
E.2.8	Genetically Modified Animals in Psychopharmacology	660
E.2.8.1	General Considerations	660
E.2.8.2	Special Reports on Genetically Altered Animals Useful for Evaluation of Drugs Against Anxiety	660
E.3	Anti-Epileptic Activity	662
E.3.0.1	General Considerations	662
E.3.1	In Vitro Methods	663
E.3.1.1	³ H-GABA Receptor Binding	663
E.3.1.2	GABA _A Receptor Binding	663
E.3.1.3	GABA _B Receptor Binding	663
E.3.1.4	³ H-GABA Uptake in Rat Cerebral Cortex Synaptosomes	663
E.3.1.5	GABA Uptake and Release in Rat Hippocampal Slices	665
E.3.1.6	Glutamate Receptors: [³ H]CPP Binding	666
E.3.1.7	NMDA Receptor Complex: [³ H]TCP Binding	670
E.3.1.8	Metabotropic Glutamate Receptors	674
E.3.1.9	Excitatory Amino Acid Transporters	677
E.3.1.10	[³⁵ S]TBPS Binding in Rat Cortical Homogenates and Sections	678
E.3.1.11	[³ H]glycine Binding in Rat Cerebral Cortex	681
E.3.1.12	[³ H]strychnine-Sensitive Glycine Receptor	683
E.3.1.13	Electrical Recordings from Hippocampal Slices in Vitro	684
E.3.1.14	Electrical Recordings from Isolated Nerve Cells	686
E.3.1.15	Isolated Neonatal Rat Spinal Cord	687
E.3.1.16	Cell Culture of Neurons	689
E.3.2	In Vivo Methods	692
E.3.2.1	Electroshock in Mice	692
E.3.2.2	Pentylentetrazol Test in Mice and Rats	693
E.3.2.3	Strychnine-Induced Convulsions in Mice	693
E.3.2.4	Picrotoxin-Induced Convulsions in Mice	693
E.3.2.5	Isoniazid-Induced Convulsions in Mice	693
E.3.2.6	Bicuculline Test in Rats	693
E.3.2.7	4-Aminopyridine-Induced Seizures in Mice	694
E.3.2.8	3-Nitropropionic Acid-Induced Seizures in Mice	694
E.3.2.9	Epilepsy Induced by Focal Lesions	695
E.3.2.10	Kindled Rat Seizure Model	697
E.3.2.11	Posthypoxic Myoclonus in Rats	698
E.3.2.12	Rat Kainate Model of Epilepsy	699
E.3.2.13	Pilocarpine Model of Epilepsy	700
E.3.2.14	Self-Sustained Status Epilepticus	701
E.3.2.15	Rat Model of Cortical Dysplasia	703
E.3.2.16	Genetic Animal Models of Epilepsy	704
E.3.2.17	Transgenic Animals as Models of Epilepsy	709
E.4	Hypnotic Activity	710
E.4.0.1	General Considerations	710
E.4.1	In Vivo Methods	710
E.4.1.1	Potentiation of Hexobarbital Sleeping Time	710
E.4.1.2	Experimental Insomnia in Rats	711
E.4.1.3	EEG Registration in Conscious Cats	712
E.4.1.4	Automated Rat Sleep Analysis System	714

E.5	Neuroleptic Activity	715
E.5.0.1	General Considerations	715
E.5.1	In Vitro Methods	715
E.5.1.1	D ₁ Receptor Assay: [³ H]-SCH 23390 Binding to Rat Striatal Homogenates	715
E.5.1.2	D ₂ Receptor Assay: [³ H]-Spiroperidol Binding	717
E.5.1.3	Dopamine D ₂ Receptor Autoradio- graphy (³ H-Spiperone Binding)	720
E.5.1.4	Binding to the D ₃ Receptor	721
E.5.1.5	Binding to D ₄ Receptors	722
E.5.1.6	Determination of Dopamine Autoreceptor Activity	724
E.5.1.7	Dopamine-Sensitive Adenylate Cyclase in Rat Striatum	725
E.5.1.8	α_1 -Adrenergic Receptor Binding in Brain	726
E.5.1.9	[³ H]Spiroperidol Binding to 5-HT ₂ Receptors in Rat Cerebral Cortex	727
E.5.1.10	Serotonin 5-HT ₂ Receptor Autoradiography (³ H-Spiperone Binding)	730
E.5.1.11	Binding to the Sigma Receptor	732
E.5.1.12	Simultaneous Determination of Norepinephrine, Dopamine, DOPAC, HVA, HIAA, and 5-HT from Rat Brain Areas	734
E.5.1.13	Measurement of Neurotransmitters by Intracranial Microdialysis	735
E.5.1.14	Use of Push-Pull Cannulae to Determine the Release of Endogenous Neurotransmitters	739
E.5.1.15	Fos Protein Expression in Brain	740
E.5.1.16	Neurotensin	742
E.5.1.16.1	General Considerations on Neurotensin and Neurotensin Receptors	742
E.5.1.16.2	Neurotensin Receptor Binding	743
E.5.1.17	Genetically Altered Monoamine Transporters	745
E.5.1.17.1	Dopamine Transporter Knockout Mice	746
E.5.1.17.2	Serotonin Transporter Knockout Mice	747
E.5.1.17.3	Noradrenaline Transporter Knockout Mice	747
E.5.2	In Vivo Tests	748
E.5.2.1	Golden Hamster Test	748
E.5.2.2	Influence on Behavior of the Cotton Rat	749
E.5.2.3	Artificial Hibernation in Rats	750
E.5.2.4	Catalepsy in Rodents	751
E.5.2.5	Pole Climb Avoidance in Rats	752
E.5.2.6	Foot-Shock Induced Aggression	752
E.5.2.7	Brain Self Stimulation	753
E.5.2.8	Prepulse Inhibition of Startle Response	754
E.5.2.9	N40 Sensory Gating	756
E.5.2.10	Latent Inhibition	757
E.5.3	Tests Based on the Mechanism of Action	759
E.5.3.1	Amphetamine Group Toxicity	759
E.5.3.2	Inhibition of Amphetamine Stereotypy in Rats	760
E.5.3.3	Inhibition of Apomorphine Climbing in Mice	761
E.5.3.4	Inhibition of Apomorphine Stereotypy in Rats	761
E.5.3.5	Yawning/Penile Erection Syndrome in Rats	762
E.5.3.6	Inhibition of Mouse Jumping	765
E.5.3.7	Antagonism Against MK-801 Induced Behavior	765
E.5.3.8	Phencyclidine Model of Psychosis	766

E.5.3.9	Inhibition of Apomorphine-Induced Emesis in the Dog	767
E.5.3.10	Purposeless Chewing in Rats	767
E.5.3.11	Models of Tardive Dyskinesia	768
E.5.3.12	Single Unit Recording of A9 and A10 Midbrain Dopaminergic Neurons	769
E.5.3.13	In Vivo Voltammetry	771
E.5.4	Genetic Models of Psychosis	773
E.5.4.1	The Heterozygous Reeler Mouse	773
E.5.4.2	The Hooded-Wistar Rat	773
E.6	Antidepressant Activity	774
E.6.0.1	General Considerations	774
E.6.1	In Vitro Methods	774
E.6.1.1	Inhibition of [³ H]-Norepinephrine Uptake in Rat Brain Synaptosomes	774
E.6.1.2	Inhibition of [³ H]-Dopamine Up- take in Rat Striatal Synaptosomes	775
E.6.1.3	Inhibition of [³ H]-Serotonin Uptake	776
E.6.1.4	Binding to Monoamine Transporters	778
E.6.1.5	Antagonism of p-Chloramphetamine Toxicity by Inhibitors of Serotonin Uptake	780
E.6.1.6	Receptor Subsensitivity After Treatment with Antidepressants: Simultaneous Determination of the Effect of Chronic Anti-Depressant Treatment on b-Adrenergic and 5-HT ₂ Receptor Densities in Rat Cerebral Cortex	781
E.6.1.7	Measurement of β -Adrenoreceptor Stimulated Adenylate Cyclase	783
E.6.1.8	[³ H]Yohimbine Binding to α_2 -Adrenoceptors in Rat Cerebral Cortex	784
E.6.1.9	Test for Anticholinergic Properties by [³ H]-QNB Binding to Muscarinic Cholinergic Receptors in Rat Brain	785
E.6.1.10	Monoamine Oxidase Inhibition: Inhibition of Type A and Type B Monoamine oxidase Activities in Rat Brain Synaptosomes	786
E.6.2	In Vivo Tests	787
E.6.2.1	Catalepsy Antagonism	787
E.6.2.2	Despair Swim Test	788
E.6.2.3	Tail Suspension Test in Mice	791
E.6.2.4	Learned Helplessness in Rats	793
E.6.2.5	Muricide Behavior in Rats	794
E.6.2.6	Behavioral Changes After Neonatal Clomipramine Treatment	795
E.6.2.7	Chronic Stress Model of Depression	797
E.6.2.8	Novelty-Induced Hypophagia Test	799
E.6.2.9	Reduction of Submissive Behavior	799
E.6.2.10	Animal Models of Bipolar Disorder	801
E.6.2.11	Animal Models of Obsessive-Compulsive Disorder	802
E.6.2.12	Antidepressant-Like Activity in Differential-Reinforcement of Low Rate 72-Second Schedule	803
E.6.3	Tests for Antidepressant Activity	804
E.6.3.1	Potentiation of Norepinephrine Toxicity	804
E.6.3.2	Compulsive Gnawing in Mice	805
E.6.3.3	Apomorphine-Induced Hypothermia in Mice	806

E.6.3.4	Tetrabenazine Antagonism in Mice	806
E.6.3.5	Reserpine-Induced Hypothermia	807
E.6.3.6	5-Hydroxytryptophan Potentiation in Mice	808
E.6.3.7	5-Hydroxytryptophan Potentiation in Rats	809
E.6.3.8	Yohimbine Toxicity Enhancement	809
E.6.3.9	Tryptamine Seizure Potentiation in Rats	810
E.6.3.10	Serotonin Syndrome in Rats	811
E.6.3.11	Hypermotility in Olfactory-Bulbectomized Rats	813
E.6.3.12	Sexual Behavior in Male Rats	815
E.6.4	Genetic Models of Depression	817
E.6.4.1	Flinders Sensitive Line of Rats	817
E.6.4.2	Genetically Altered Mice as Models of Depression	818
E.7	Anti-Parkinsonism Activity	820
E.7.0.1	General Considerations	820
E.7.1	In Vitro Methods	821
E.7.1.1	Culture of Substantia Nigra	821
E.7.1.2	Inhibition of Apoptosis in Neuroblastoma SH-SY5Y Cells	822
E.7.2	In Vivo Methods	824
E.7.2.1	Tremorine and Oxotremorine Antagonism	824
E.7.2.2	MPTP Model of Parkinson's Disease	826
E.7.2.3	Reserpine Antagonism	828
E.7.2.4	Circling Behavior in Nigrostriatal Lesioned Rats	829
E.7.2.5	Elevated Body Swing Test	832
E.7.2.6	Skilled Paw Reaching in Rats	832
E.7.2.7	Stepping Test in Rats	834
E.7.2.8	Transgenic Animal Models of Parkinson's Disease	835
E.7.2.9	Cell Transplantations into Lesioned Animals	837
E.7.2.10	Transfer of Glial Cell Line-Derived Neurotrophic Factor (GDNF)	838
E.8	Animal Models of Neurological Disorders	839
E.8.1	Huntington's Disease	839
E.8.1.1	General Considerations	839
E.8.1.2	3-Nitropropionic Acid Animal Model of Huntington's Disease	839
E.8.1.3	Quinolinic Acid Rat Model of Huntington's Disease	841
E.8.1.4	Transgenic Animal Models of Huntington's Disease	842
E.8.2	Amyotrophic Lateral Sclerosis	843
E.8.2.1	General Considerations	843
E.8.2.2	Transgenic Animal Models of Amyotrophic Lateral Sclerosis	844
E.8.3	Spinal Muscular Atrophy	846
E.8.3.1	General Considerations	846
E.8.3.2	Transgenic Animal Models of Spinal Muscular Atrophy	846
E.8.4	Spinal and Bulbar Muscular Atrophy	849
E.8.4.1	General Considerations	849
E.8.4.2	Transgenic Animal Models of Spinal and Bulbar Muscular Atrophy	849
E.8.5	Models of Down Syndrome	850
E.8.6	Models of Wilson's Disease	852
E.8.7	Models of Cerebellar Ataxia	853
E.8.8	Models of Niemann-Pick Syndrome	854
E.8.9	Models of Gangliosidosis	855
E.8.10	Models of Mucopolysaccharidosis	856

E.9	General Anesthesia	857
E.9.1	Intravenous Anesthesia	857
E.9.1.1	General Considerations	857
E.9.1.2	Screening of Intravenous Anesthetics	858
E.9.1.3	EEG Threshold Test in Rats	859
E.9.1.4	Efficacy and Safety of Intravenous Anesthetics	860
E.9.2	Inhalation Anesthesia	861
E.9.2.1	General Considerations	861
E.9.2.2	Screening of Volatile Anesthetics	861
E.9.2.3	Determination of Minimal Alveolar Anesthetic Concentration (MAC)	862
E.9.2.4	Efficacy and Safety of Inhalation Anesthetics	863
E.10	NMRI Methods in Psychoneuropharmacology	866
E.10.1	General Considerations	866
E.10.2	NMRI Psychopharmacological Studies in Rats	866
E.10.2.1	NMRI Study of Experimental Allergic Encephalomyelitis in Rats	866
E.10.2.2	NMRI Study of 3-Nitropropionic Acid-Induced Neurodegeneration in Rats	868
E.10.2.3	NMRI Studies of Brain Activation in Rats	869
E.10.3	NMRI Psychoneuropharmacological Studies in Primates	872
E.10.3.1	Functional NMRI Studies in the Brain of Rhesus Monkeys	872
E.10.3.2	Functional NMRI Studies in the Brain of Common Marmosets	874
Chapter F		
	Drug Effects on Learning and Memory	877
F.1	Introduction	878
F.2	In Vitro Methods	880
F.2.0.1	In Vitro Inhibition of Acetylcholine-Esterase Activity in Rat Striatum	880
F.2.0.2	In Vitro Inhibition of Butyrylcholine-Esterase Activity in Human Serum	882
F.2.0.3	Ex Vivo Cholinesterase Inhibition	882
F.2.0.4	Molecular Forms of Acetylcholinesterase from Rat Frontal Cortex and Striatum	884
F.2.0.5	Release of [³ H]ACh and Other Transmitters from Rat Brain Slices	886
F.2.0.6	[³ H]Oxotremorine-M Binding to Muscarinic Cholinergic Receptors in Rat Forebrain	890
F.2.0.7	[³ H]N-Methylscopolamine Binding in the Presence and Absence of Gpp(NH)p	891
F.2.0.8	Stimulation of Phosphatidylinositol Turnover in Rat Brain Slices	892
F.2.0.9	[³ H]N-Methylcarbamylcholine Binding to Nicotinic Cholinergic Receptors in Rat Frontal Cortex	895
F.2.0.10	Uncompetitive NMDA Receptor Antagonism	897
F.2.0.11	Secretion of Nerve Growth Factor by Cultured Neurons/Astroglial Cells	898
F.2.0.12	Inhibition of Respiratory Burst in Microglial Cells/Macrophages	901

F.3	In Vivo Methods	902
F.3.1	Inhibitory (Passive) Avoidance	902
F.3.1.1	Step-down	902
F.3.1.2	Step-through	903
F.3.1.3	Two Compartment Test	905
F.3.1.4	Up-Hill Avoidance	905
F.3.1.5	Trial-to-criteria inhibitory avoidance	906
F.3.1.6	Scopolamine-Induced Amnesia in Mice	906
F.3.1.7	Cognitive Deficits on Chronic Low Dose Mptp-Treated Monkeys	908
F.3.2	Active Avoidance	909
F.3.2.1	Runway Avoidance	909
F.3.2.2	Shuttle Box Avoidance (Two-Way Shuttle Box)	910
F.3.2.3	Jumping Avoidance (One-Way Shuttle Box)	910
F.3.3	Discrimination Learning	911
F.3.3.1	Spatial Habituation Learning	911
F.3.3.2	Spatial Discrimination	913
F.3.3.3	Spatial Learning in the Radial Arm Maze	913
F.3.3.4	Visual Discrimination	914
F.3.3.5	Spatial Learning in the Water Maze	915
F.3.3.6	Active Allothetic Place Avoidance Task	917
F.3.3.7	Olfactory Learning	918
F.3.3.8	Aversive Discrimination in Chickens	919
F.3.4	Conditioned Responses	921
F.3.4.1	Conditioned Nictitating Membrane Response in Rabbits	921
F.3.4.2	Automated Learning and Memory Model in Mice	923
F.3.4.3	Learning Deficits After Postnatal Anoxia in Rats	924
F.3.5	Studies in Monkeys	925
F.3.6	Electrophysiological Methods	926
F.3.6.1	Long-Term Potentiation in Hippocampal Slices	926
F.3.6.2	Long Term Potentiation in Vivo	927
F.3.6.3	Long Latency Averaged Potentials	929
F.3.7	Metabolic Influence	930
F.3.7.1	Sodium Nitrite Intoxication (NaNO ₂)	930
F.4	Animals with Memory Deficits	930
F.4.1	Memory Deficits After Cerebral Lesions	930
F.4.2	Cognitive Deficits After Cerebral Ischemia	935
F.4.3	Strains with Hereditary Memory Deficits	937
F.4.4	Genetically Modified Animals	937
F.4.5	Studies in Invertebrate Animals	941
F.4.5.1	Studies in <i>Caenorhabditis Elegans</i>	941
F.4.5.2	Studies in <i>Drosophila</i>	942

Chapter G**Effects On Peripheral Nerve Function 943**

G.1	Local Anesthetic Activity	943
G.1.0.1	General Considerations	943
G.1.1	Conduction Anesthesia	944
G.1.1.1	Conduction Anesthesia in the Sciatic Nerve of the Frog	944
G.1.1.2	Conduction Anesthesia in the Sciatic Nerve of the Rat	945
G.1.1.3	Conduction Anesthesia on the Mouse Tail	946

G.1.1.4	Rabbit Tooth Pulp Assay	948
G.1.1.5	Infraorbital Nerve Block in the Rat	949
G.1.1.6	Retrobulbar Block in Dogs	949
G.1.1.7	Isolated Sciatic Nerve Preparation of the Frog	950
G.1.1.8	Isolated Mammalian Sciatic Nerve Preparation	951
G.1.1.9	Effect of Local Anesthetics on Different Nerve Fibers	952
G.1.1.10	Measurement of Sodium and Potassium Conductance in Voltage Clamp Experiments	953
G.1.1.11	Inhibition of Fast Axonal Transport	956
G.1.2	Infiltration Anesthesia	957
G.1.2.1	Infiltration Anesthesia in Guinea Pig's Wheals	957
G.1.2.2	Infiltration Anesthesia in Mice	958
G.1.3	Surface Anesthesia	958
G.1.3.1	Surface Anesthesia on the Cornea of Rabbits	958
G.1.3.2	Suppression of Sneezing Reflex in Rabbits	959
G.1.4	Epidural Anesthesia	960
G.1.4.1	Epidural Anesthesia in Various Species	960
G.1.5	Intrathecal (Spinal) Anesthesia	963
G.1.5.1	Spinal Anesthesia in Various Species	963
G.1.5.2	Blockade of Urethral Reflex in Rabbits	970
G.1.6	Endoanesthetic Effect	970
G.1.7	Effect on Electroretinogram	972
G.2	Neuromuscular Blocking Activity	973
G.2.0.1	General Considerations	973
G.2.0.2	Isolated Phrenic Nerve Diaphragm Preparation of the Rat	974
G.2.0.3	Sciatic Nerve-Gastrocnemius Muscle Preparation in the Rabbit	977
G.2.0.4	Evaluation of Neuromuscular Blockade in Cats, Pigs, Dogs and Monkeys	977
G.2.0.5	Evaluation of Neuromuscular Blockade in Anesthetized Mice	981
G.3	Safety Pharmacology	981

Volume 2

Chapter H

Analgesic, Anti-Inflammatory, and Anti-Pyretic Activity 983

H.1	Central Analgesic Activity	984
H.1.0.1	General Considerations	984
H.1.1	In Vitro Methods for Central Analgesic Activity	985
H.1.1.1	Survey	985
H.1.1.2	³ H-Naloxone Binding Assay	989
H.1.1.3	³ H-Dihydromorphine Binding to μ Opiate Receptors in Rat Brain	990
H.1.1.4	³ H-Bremazocine Binding to κ Opiate Receptors in Guinea Pig Cerebellum	991
H.1.1.5	Inhibition of Enkephalinase	993
H.1.1.6	Nociceptin	994
H.1.1.6.1	General Considerations on Nociceptin	994
H.1.1.6.2	Receptor Binding of Nociceptin	995
H.1.1.6.3	Bioassays for Nociceptin	996

H.1.1.7	Vasoactive Intestinal Polypeptide (VIP) and Pituitary Adenylate Cyclase-Activating Peptide (PACAP)	998
H.1.1.8	Cannabinoid Activity	1000
H.1.1.8.1	General Considerations on Cannabinoids	1000
H.1.1.8.2	Receptor Binding of Cannabinoids	1003
H.1.1.9	Vanilloid (Capsaicin) Activity	1005
H.1.1.9.1	General Considerations on Vanilloids	1005
H.1.1.9.2	Vanilloid Receptor Binding	1007
H.1.1.9.3	Evaluation of Vanilloid Receptor Antagonists	1008
H.1.2	In Vivo Methods for Testing Central Analgesic Activity	1010
H.1.2.1	General Considerations	1010
H.1.2.2	Haffner's Tail Clip Method	1010
H.1.2.3	Radiant Heat Method	1011
H.1.2.4	Hot Plate Method	1013
H.1.2.5	Tail Immersion Test	1014
H.1.2.6	Electrical Stimulation of the Tail	1016
H.1.2.7	Grid Shock Test	1017
H.1.2.8	Tooth Pulp Stimulation	1018
H.1.2.9	Monkey Shock Titration Test	1019
H.1.2.10	Formalin Test in Rats	1020
H.1.2.11	Neuropathic Pain	1022
H.1.2.11.1	General Considerations	1022
H.1.2.11.2	Chronic Nerve Constriction Injury	1022
H.1.2.11.3	Peripheral Nerve Injury Model	1024
H.1.2.11.4	Spared Nerve Injury Model	1025
H.1.2.11.5	Spinal Cord Injury	1026
H.1.2.11.6	Chemotherapy-Induced Pain	1028
H.1.2.11.7	Trigeminal Neuropathic Pain Model	1029
H.1.2.11.8	Migraine Model in Cats	1030
H.1.3	Side Effects of Central Analgesic Drugs	1030
H.2	Peripheral Analgesic Activity	1030
H.2.0.1	General Considerations	1030
H.2.0.2	Writhing Tests	1031
H.2.0.3	Pain in Inflamed Tissue (RANDALL-SELITTO-Test)	1032
H.2.0.4	Mechanical Visceral Pain Model in the Rat	1035
H.2.0.5	Antagonism Against Local Effects of Bradykinin	1036
H.2.0.6	Effect of Analgesics on Spinal Neurons	1038
H.2.0.7	Antagonism to Nerve Growth Factor	1041
H.2.0.7.1	General Considerations on Nerve Growth Factor	1041
H.2.0.7.2	In Vitro Assays of Nerve Growth Factor	1041
H.2.0.7.3	In Vivo Assays of Nerve Growth Factor Antagonism	1043
H.3	Anti-Inflammatory Activity	1047
H.3.0.1	General Considerations	1047
H.3.1	In Vitro Methods for Anti-Inflammatory Activity	1047
H.3.1.1	General Considerations	1047
H.3.1.2	³ H-Bradykinin Receptor Binding	1048
H.3.1.3	Substance P and the Tachykinin Family	1051
H.3.1.3.1	General Considerations	1051
H.3.1.3.2	³ H-Substance P Receptor Binding	1053
H.3.1.3.3	Neurokinin Receptor Binding	1053
H.3.1.3.4	Characterization of Neurokinin Agonists and Antagonists by Biological Assays	1055

H.3.1.4	Assay of Polymorphonuclear Leukocyte Chemotaxis In Vitro .	1058
H.3.1.5	Polymorphonuclear Leukocytes Aggregation Induced by FMLP	1059
H.3.1.6	Constitutive and Inducible Cellular Arachidonic Acid Metabolism Metabolism In Vitro	1060
H.3.1.6.1	Formation of Leukotriene B ⁴ in Human White Blood Cells In Vitro	1061
H.3.1.6.2	Formation of Lipoxygenase Products from ¹⁴ C-Arachidonic Acid in Human Polymorpho- nuclear Neutrophils (PMN) In Vitro	1061
H.3.1.6.3	Formation of Eicosanoids from ¹⁴ C-Arachidonic Acid in Human Platelets In Vitro	1062
H.3.1.6.4	Stimulation of Inducible Prostaglandin Pathway in Human PMNL	1062
H.3.1.6.5	COX-1 and COX-2 Inhibition	1063
H.3.1.7	Influence of Cytokines	1069
H.3.1.7.1	Induced Release of Cytokines (Interleukin-1 α , IL-1 β , IL-6, IL-8 and TNF α) from Human White Blood Cells In Vitro . . .	1069
H.3.1.7.2	Flow Cytometric Analysis of Intracellular Cytokines	1071
H.3.1.7.3	Screening for Interleukin-1 Antagonists	1072
H.3.1.7.4	Inhibition of Interleukin-1 β Converting Enzyme (ICE)	1074
H.3.1.7.5	Nuclear Factor- κ B	1076
H.3.1.8	TNF- α Antagonism	1081
H.3.1.8.1	General Considerations	1081
H.3.1.8.2	Inhibition of TNF- α Release	1083
H.3.1.8.3	Effect of TNF- α Binding	1084
H.3.1.9	Binding to Interferon Receptors	1087
H.3.1.10	Chemokine Antagonism	1089
H.3.1.11	Influence of Peroxisome Proliferator-Activated Receptors (PPARs) on Inflammation	1091
H.3.1.12	Binding to Histamine H ⁴ Receptor	1093
H.3.2	In Vivo Methods for Anti-inflammatory Activity	1094
H.3.2.1	General considerations	1094
H.3.2.2	Methods for Testing Acute and Subacute Inflammation	1095
H.3.2.2.1	Ultraviolet Erythema in Guinea Pigs	1095
H.3.2.2.2	Vascular Permeability	1096
H.3.2.2.3	Inhibition of Leukocyte Adhesion to Rat Mesenteric Venules In Vivo	1098
H.3.2.2.4	Oxazolone-Induced Ear Edema in Mice	1099
H.3.2.2.5	Croton-oil Ear Edema in Rats and Mice	1100
H.3.2.2.6	Paw Edema	1103
H.3.2.2.7	Pleurisy Test	1106
H.3.2.2.8	Granuloma Pouch Technique	1107
H.3.2.2.9	Urate-Induced Synovitis	1109
H.3.2.3	Methods for Testing the Proliferative Phase (Granuloma Formation)	1110
H.3.2.3.1	Cotton Wool Granuloma	1110
H.3.2.3.2	Sponge Implantation Technique	1111
H.3.2.3.3	Glass Rod Granuloma	1113
H.3.3	Side Effects of Anti-inflammatory Compounds	1113
H.4	Antipyretic Activity	1113
H.4.0.1	General Considerations	1113

H.4.0.2	Antipyretic Testing in Rats	1114
H.4.0.3	Antipyretic Testing in Rabbits	1115

Chapter I

Antiarthrotic and Immunomodulatory Activity 1117

I.1	Anti-Arthrotic Activity	1118
I.1.0.1	General Considerations	1118
I.1.1	In Vitro Methods for Anti-Osteoarthritic Activity	1118
I.1.1.1	General Considerations	1118
I.1.1.2	Modulation of Cellular Proteoglycan Metabolism	1119
I.1.1.3	Cellular Chondrocytic Chondrolysis	1122
I.1.1.4	Cartilage Explant Chondrolysis	1123
I.1.1.5	Influence on Matrix Metalloproteases	1125
I.1.1.6	Aggrecanase Inhibition	1129
I.1.2	In Vivo Methods for Anti- Osteoarthritic Activity	1131
I.1.2.1	General Considerations	1131
I.1.2.2	Canine Anterior Cruciate Ligament (ACL) Transection Model	1134
I.1.2.3	Chymopapain-Induced Cartilage Degeneration in the Rabbit .	1137
I.1.2.4	Spontaneous OA Model in STR/1N Mice	1139
I.1.2.5	Transgenic Mice as Models of Osteoarthritis	1141
I.2	Methods for Testing Immunological Factors	1143
I.2.1	In Vitro Methods	1143
I.2.1.1	Inhibition Of Histamine Release from Mast Cells	1143
I.2.1.2	Mitogen Induced Lymphocyte Proliferation	1144
I.2.1.3	Inhibition of T Cell Proliferation	1145
I.2.1.4	Chemiluminescence in Macrophages	1146
I.2.1.5	PFC (Plaque Forming Colony) Test In Vitro	1148
I.2.1.6	Inhibition of Dihydro-Orotate Dehydrogenase	1148
I.2.1.7	Sphingosine 1-Phosphate	1149
I.2.1.7.1	General Considerations	1149
I.2.1.7.2	Binding to Sphingosine 1-Phosphate Receptors	1150
I.2.1.7.3	Sphingosine Kinase Activation Assay	1152
I.2.1.7.4	Lymphocyte Trafficking After Sphingosine 1-Phosphate Receptor Agonists	1153
I.2.2	In Vivo Methods for Testing Immunological Factors	1155
I.2.2.1	Spontaneous Autoimmune Diseases in Animals	1155
I.2.2.2	Acute Systemic Anaphylaxis in Rats	1157
I.2.2.3	Anti-Anaphylactic Activity (Schultz–Dale Reaction)	1158
I.2.2.4	Passive Cutaneous Anaphylaxis	1159
I.2.2.5	Arthus Type Immediate Hypersensitivity	1160
I.2.2.6	Delayed Type Hypersensitivity	1161
I.2.2.7	Reversed Passive Arthus Reaction	1161
I.2.2.8	Adjuvant Arthritis in Rats	1162
I.2.2.9	Collagen Type II Induced Arthritis in Rats	1167
I.2.2.10	Proteoglycan-Induced Progressive Polyarthritis in Mice	1170
I.2.2.11	Pristane-Induced Arthritis in Mice	1171
I.2.2.12	Experimental Autoimmune Thyroiditis	1174
I.2.2.13	Coxsackievirus B3-Induced Myocarditis	1175
I.2.2.14	Porcine Cardiac Myosin-Induced Autoimmune Myocarditis in Rats	1176
I.2.2.15	Experimental Allergic Encephalomyelitis	1177

I.2.2.16	Acute Graft Versus Host Disease (GVHD) in Rats	1180
I.2.2.17	Influence on SLE-Like Disorder in MRL/lpr Mice	1181
I.2.2.18	Prevention of Experimentally Induced Myasthenia Gravis in Rats	1184
I.2.2.19	Glomerulonephritis Induced by Antibasement Membrane Antibody in Rats	1185
I.2.2.20	Auto-Immune Uveitis in Rats	1187
I.2.2.21	Inhibition of Allogenic Transplant Rejection	1187

Chapter J

Activity on the Gastrointestinal Tract 1191

J.1	Salivary Glands	1193
J.1.0.1	Measurement of Salivation	1193
J.2	Esophagus	1195
J.2.0.1	Tunica Muscularis Mucosae of Esophagus In Vitro	1195
J.2.0.2	Esophageal Sphincter In Vivo	1198
J.2.0.3	Permanent Fistula of the Esophagus in the Dog	1199
J.3	Gastric Function	1200
J.3.1	Acid Secretion	1200
J.3.1.1	Acid Secretion in Perfused Rat Stomach (Gosh and Schild Rat)	1200
J.3.1.2	Isolated Rat Stomach	1201
J.3.1.3	Chronic Gastric Fistula in Rats	1202
J.3.1.4	Chronic Gastric Fistula in Dogs	1204
J.3.1.5	Heidenhain Pouch in Dogs	1204
J.3.1.6	Gastrin Activity	1207
J.3.1.7	Receptor Binding for Gastrin	1208
J.3.1.8	Gastrin Releasing Peptide/Bombesin/Neuromedin	1209
J.3.1.9	Bombesin Receptor Binding	1211
J.3.1.10	Evaluation of Bombesin Receptor Antagonists as Anti-Cancer Drugs	1213
J.3.2	Mucus Secretion	1216
J.3.2.1	Isolated Gastric Mucosal Preparation	1216
J.3.2.2	Primary Culture of Rat Gastric Epithelial Cells	1217
J.3.3	Gastric Motility	1218
J.3.3.1	Measurement of Intra-gastric Pressure in Rats	1218
J.3.3.2	Isolated Smooth Muscle Preparation of Guinea Pig Stomach	1218
J.3.4	Absorption	1219
J.3.4.1	Measurement of Gastric Absorption of Drugs in Rats	1219
J.3.5	Antacid Activity	1220
J.3.5.1	Evaluation of Antacids	1220
J.3.6	Inhibition of HCl Secretion	1221
J.3.6.1	Anticholinergic Activity	1221
J.3.6.1.1	General Considerations	1221
J.3.6.1.2	Acetylcholine Receptor Binding	1222
J.3.6.2	H ₂ -Antagonism	1225
J.3.6.2.1	General Considerations	1225
J.3.6.2.2	Histamine H ₂ -Receptor Binding	1226
J.3.6.2.3	H ₂ -Antagonism in Isolated Guinea Pig Right Atria	1227
J.3.6.2.4	H ₂ -Antagonism in Isolated Rat Uterus	1227
J.3.6.2.5	Activity at Histamine H ₁ - and H ₂ -Receptors In Vivo	1228

J.3.6.2.6	Inhibition of Histamine Stimulated Adenylate Cyclase from Gastric Mucosa	1229
J.3.6.3	H ⁺ /K ⁺ -ATPase (Proton Pump) Inhibition	1230
J.3.6.3.1	General Considerations	1230
J.3.6.3.2	H ⁺ /K ⁺ -ATPase Inhibition in Membrane Vesicles of Stomach Mucosa	1230
J.3.6.3.3	Effect of H ⁺ /K ⁺ -ATPase Inhibitors on Serum Gastrin Levels .	1231
J.3.6.3.4	(¹⁴ C)-Aminopyrine Uptake and Oxygen Consumption in Isolated Rabbit Gastric Glands	1232
J.3.6.3.5	Gastric Mucosal Blood Flow	1234
J.3.7	Anti-Ulcer Activity	1235
J.3.7.1	Pylorus Ligation in Rats (SHAY Rat)	1235
J.3.7.2	Indomethacin Induced Ulcers in Rats	1236
J.3.7.3	Ethanol Induced Mucosal Damage in Rats (Cytoprotective Activity)	1237
J.3.7.4	Subacute Gastric Ulcer in Rats	1239
J.3.7.5	Gastric Ischemia-Reperfusion Injury in Rats	1240
J.4	Intestinal Functions	1241
J.4.1	Intestinal Secretion	1241
J.4.1.1	Laxative Activity in Rats	1241
J.4.1.2	Enteropooling Test	1241
J.4.1.3	Inhibition of Chloride Secretion in Rabbit Colon	1242
J.4.2	Antidiarrhea Effect	1243
J.4.2.1	Castor Oil Induced Diarrhea	1243
J.4.2.2	Antidiarrheal Effect in Cecectomized Rats	1244
J.4.2.3	Evaluation of Antidiarrheal Effect in Cold-Restrained Rats . .	1245
J.4.3	Gut Motility	1246
J.4.3.1	Isolated Ileum (MAGNUS Technique)	1246
J.4.3.2	Cascade Superfusion Technique	1248
J.4.3.3	In Vivo Evaluation of Spasmolytic Activity in Rats	1249
J.4.3.4	Colon Motility in Anesthetized Rats	1250
J.4.3.5	Continuous Recording of Electrical and Mechanical Activity in the Gut of the Conscious Rat	1251
J.4.3.6	Propulsive Gut Motility in Mice	1252
J.4.3.7	Nerve-Jejunum Preparation of the Rabbit	1253
J.4.3.8	Motility of Gastrointestinal Tract in Dogs	1253
J.4.3.9	Thiry-Vella Fistula	1254
J.4.3.10	Continuous Recording of Mechanical and Electrical Activity in the Intestine of Conscious Dogs	1256
J.4.4	Absorption	1258
J.4.4.1	Everted Sac Technique	1258
J.4.4.2	Stomach Emptying and Intestinal Absorption in Rats	1259
J.4.4.3	Intestinal Drug Absorption	1261
J.4.5	Duodenal Ulcer Formation	1262
J.4.5.1	Cysteamine-Induced Duodenal Ulcers in Rats	1262
J.4.6	Models of Inflammatory Gut Disease	1263
J.4.6.1	Experimental Ileitis	1263
J.4.6.2	Experimental Colitis	1265
J.5	Emetic and Anti-Emetic Activity	1271
J.5.0.1	Assessment of Emetic and Anti-Emetic Activity in Dogs . . .	1271
J.5.0.2	Anti-Emetic Activity in Ferrets	1272
J.5.0.3	Assessment of Emetic and Anti-Emetic Activity in Pigeons .	1273

J.5.0.4	Activity Against Motion- Induced Emesis	1274
J.5.0.5	Foot Tapping in Gerbils	1275
J.6	Gall Bladder Functions	1275
J.6.1	Bile Secretion	1275
J.6.1.1	Cholagogic Activity in Mice	1275
J.6.1.2	Choleretic Activity in Rats	1276
J.6.1.3	Chronic Bile Fistula in Rats	1277
J.6.1.4	Chronic Bile Fistula in Dogs	1279
J.6.1.5	Prevention of Experimental Cholelithiasis	1280
J.6.2	Gall Bladder Motility	1281
J.6.2.1	Activity on Isolated Gall- Bladder Strips from Guinea Pigs . .	1281
J.6.2.2	Gallbladder Motility in Dogs	1281
J.6.2.3	Cholecystokinin Activity (Isolated Gallbladder or Intestine)	1282
J.6.3	Sphincter Oddi Function	1283
J.6.3.1	Relaxation of Sphincter of Oddi In Vitro	1283
J.6.3.2	Function of Sphincter of Oddi In Vivo	1284
J.7	Pancreatic Function	1285
J.7.0.1	Acute Pancreatic Fistula in Rats	1285
J.7.0.2	Exocrine Secretion of Isolated Pancreas	1286
J.7.0.3	Chronic Pancreatic Fistula in Rats	1287
J.7.0.4	Acute Pancreatic Fistula in Dogs	1288
J.7.0.5	Chronic Pancreatic Fistula in Dogs	1289
J.7.0.6	Somatostatin Activity	1290
J.7.0.7	Receptor Binding for Somatostatin	1293
J.7.0.8	Secretin Activity	1296
J.7.0.9	Receptor Binding for Secretin	1296
J.7.0.10	Cholecystokinin Activity (Isolated Rat Pancreatic Acini) . . .	1298
J.7.0.11	Receptor Binding of Cholecystokinin	1299
J.7.0.12	Acute Experimental Pancreatitis	1303
J.7.0.13	Taurocholate-Induced Pancreatitis in the Rat	1306
J.7.0.14	Chronic Pancreatitis	1307
J.8	Liver Function	1309
J.8.1	Hepatocellular Function	1309
J.8.1.1	Hepatitis in Long Evans Cinnamon Rats	1309
J.8.1.2	Temporary Hepatic Ischemia	1310
J.8.1.3	Model for Direct Transhepatic Studies in Dogs	1311
J.8.2	Liver Cirrhosis and Necrosis	1312
J.8.2.1	General Considerations	1312
J.8.2.2	Inhibition of Proline Hydroxylation	1313
J.8.2.3	Influence on Collagen Synthesis in Human Skin Fibroblasts	1313
J.8.2.4	Influence on Collagen Synthesis in Chicken Calvaria	1314
J.8.2.5	Allyl Alcohol Induced Liver Necrosis in Rats	1315
J.8.2.6	Carbontetrachloride Induced Liver Fibrosis in Rats	1315
J.8.2.7	Bile Duct Ligation Induced Liver Fibrosis in Rats	1317
J.8.2.8	Galactosamine Induced Liver Necrosis	1318
J.8.2.9	Liver Fibrosis Induced by Schistosome Cercariae	1319
J.9	Eviscerated Animals	1319
J.9.1	Evisceration in Rats	1319
J.9.2	Evisceration in Rabbits	1320
J.10	Safety Pharmacology of Gastrointestinal Drugs	1321

Chapter K**Antidiabetic Activity 1323****K.1 Methods to Induce Experimental Diabetes Mellitus 1327**

K.1.1 Pancreatectomy in Dogs 1327

K.1.2 Alloxan-Induced Diabetes 1329

K.1.3 Streptozotocin-Induced Diabetes 1330

K.1.4 Other Diabetogenic Compounds 1331

K.1.5 Growth Hormone-Induced Diabetes 1331

K.1.6 Corticosteroid-Induced Diabetes 1332

K.1.7 Insulin Deficiency Due to Insulin Antibodies 1332

K.1.8 Virus-Induced Diabetes 1332

K.2 Genetically Diabetic Animals 1333

K.2.1 Spontaneously Diabetic Rats 1334

K.2.2 Spontaneously Diabetic Mice 1338

K.2.3 Chinese Hamster 1341

K.2.4 Other Species with Inherited Diabetic Symptoms 1342

K.2.5 Transgenic Animals and Knockout Mice 1343

K.2.6 Metabolic Systems Biology 1347

K.3 Measurement of Blood Glucose-Lowering and Antidiabetic Activity 1349

K.3.1 Hypoglycemic Effects 1349

K.3.1.1 Blood Glucose-Lowering Effect in Rabbits 1349

K.3.1.2 Blood Glucose-Lowering Effect in Rats 1351

K.3.1.3 Blood Glucose-Lowering Effect in Mice 1352

K.3.1.4 Blood Glucose-Lowering Effect in Dogs 1352

K.3.1.5 Blood Glucose-Lowering Effect in Other Species 1353

K.3.2 Euglycemic Clamp Technique 1353

K.3.3 Hypoglycemic Seizures in Mice 1355

K.3.4 Effects of Insulin Sensitizer Drugs 1356

K.3.5 Effects of Thiazolidinediones on Peroxisome Proliferator- Activated Receptor- γ 1358

K.3.6 Antidiabetic Effects of Liver X Receptor Agonists 1362

K.4 Measurement of Insulin and Other Glucose-Regulating Peptide Hormones 1363

K.4.1 Radioimmunoassays for Insulin, Glucagon and Somatostatin 1363

K.4.2 Bioassay for Glucagon 1365

K.4.3 Receptor Binding and In Vitro Activity of Glucagon 1366

K.4.4 Glucagon-Like Peptide I 1367

K.4.5 Insulin-Like Growth Factors 1369

K.4.6 Amylin 1372

K.5 Insulin Target Tissues and Cells 1375

K.5.1 Adipose Tissue and Adipocytes 1375

K.5.1.1 Epididymal Fat Pads of Rats 1375

K.5.1.2 Primary Rat Adipocytes 1376

K.5.1.3 Insulin-Resistant Primary Rat Adipocytes 1378

K.5.1.4 Cultured Mouse Adipocytes 1379

K.5.1.4.1 3T3-L1 Adipocytes 1379

K.5.1.4.2 OP9 Adipocytes 1380

K.5.1.5 Cultured Human Adipocytes 1381

K.5.1.5.1 Adipocytes Derived from Human Adipose-Derived Adult Stem (ADAS) Cells 1381

K.5.1.5.2	Adipocytes Derived from Commercially Available Human Preadipocytes	1382
K.5.1.6	Adipocyte–Myocyte Co-Culture	1383
K.5.1.7	Adipocytes Derived from Mouse Embryonic Fibroblasts (MEF)	1384
K.5.1.8	Brown Adipocytes	1384
K.5.1.9	Conditionally Immortalized Cell Strains	1384
K.5.2	Liver and Hepatocytes	1386
K.5.2.1	Perfused Rat Liver	1386
K.5.2.2	Primary Rat Hepatocytes	1387
K.5.2.3	Cultured Human Hepatocytes	1387
K.5.3	Muscle Tissue and Myocytes	1387
K.5.3.1	Perfused Rat Hindlimb	1388
K.5.3.2	Rat Diaphragms	1388
K.5.3.3	Rat Soleus and Extensor Digitorum Longus	1389
K.5.3.4	Human Muscle Strips	1389
K.5.3.5	Cultured Human Skeletal Muscle Cells	1389
K.5.3.6	L6 Myotubes	1389
K.5.3.7	L6 Myotubes Transfected with GLUT4	1390
K.5.3.8	BC ₃ H ₁ Myocytes	1390
K.5.3.9	C ₂ C ₁₂ Myotubes	1390
K.5.3.10	Cardiomyocytes	1390
K.5.4	Pancreas and Pancreatic β -Cells	1391
K.5.4.1	Perfused Rat Pancreas	1391
K.5.4.2	Perifused Islets	1392
K.5.4.3	Insulinoma Cells	1392
K.5.4.4	Cultured β -Cells	1392
K.6	Assays for Insulin and Insulin- Like Metabolic Activity . .	1396
K.6.1	Assays for Insulin and Insulin-Like Activity Based on Adipocytes	1397
K.6.1.1	Differentiation	1397
K.6.1.2	Lipogenesis	1398
K.6.1.2.1	Method Based on the Incorporation of Radiolabeled Glucose .	1398
K.6.1.2.2	Method Based on the Incorporation of a Fluorescent Fatty Acid Analog	1399
K.6.1.3	Glucose Transport	1400
K.6.1.3.1	Method Based on Radiolabeled 2-Deoxyglucose	1401
K.6.1.3.2	Method Based on Unlabeled 2-Deoxyglucose	1402
K.6.1.3.3	Method Based on 3- <i>O</i> -Methylglucose	1403
K.6.1.3.4	Method Based on a Fluorescent Glucose Analog	1403
K.6.1.4	Glucose Transporter Translocation	1404
K.6.1.4.1	Methods Based on the Determination of GLUT Molecules in Isolated Plasma Membranes	1405
K.6.1.4.2	Methods Based on the Determination of GLUT Molecules at the Plasma Membranes of Intact Cells	1406
K.6.1.4.3	Method Based on the Reconstitution of GLUT4 Translocation	1409
K.6.1.5	Fatty Acid Transport	1414
K.6.1.5.1	Method Based on Radiolabeled Fatty Acids	1415
K.6.1.5.2	Method Based on Fluorescent Fatty Acids	1416
K.6.1.6	Cellular Esterification	1417
K.6.1.7	Lipid-Synthesizing Enzymes	1418
K.6.1.7.1	Glycerol-3-Phosphate Acyltransferase (GPAT)	1418

K.6.1.7.2	Acylglycerol-3-Phosphate Acyltransferase (AGPAT)	1419
K.6.1.7.3	Diacylglycerol Acyltransferase (DGAT)	1419
K.6.1.8	Formation of Lipid Droplets	1420
K.6.1.8.1	Preparation of Microsomes	1420
K.6.1.8.2	Cell-Free System	1420
K.6.1.8.3	Characterization of Lipid Droplets	1421
K.6.1.9	Re-Esterification	1422
K.6.1.10	Cellular Lipolysis	1423
K.6.1.10.1	Method Based on Isolated Fat Pads	1424
K.6.1.10.2	Method Based on the Release of Fluorescent Fatty Acids from Isolated Adipocytes	1424
K.6.1.10.3	Method Based on the Release of Glycerol from Isolated Adipocytes	1425
K.6.1.10.4	Method Based on the Release of [³ H]Oleic Acid from Isolated Adipocytes	1425
K.6.1.10.5	Method Based on the Release of Unlabeled Fatty Acids from Isolated Adipocytes	1425
K.6.1.11	Cell-Free Lipolysis	1426
K.6.1.12	Translocation of Hormone- Sensitive Lipase (HSL)	1427
K.6.1.12.1	Protein Composition of LD	1428
K.6.1.12.2	Interaction of HSL and Perilipin	1430
K.6.1.13	Triacylglycerol (TAG) Lipases (HSL, ATGL) Activity	1431
K.6.1.13.1	Method Based on Fluorescently Labeled Monoacylglycerol (NBD-MAG)	1434
K.6.1.13.2	Method Based on Fluorescently Labeled TAG	1435
K.6.1.13.3	Method Based on Radiolabeled Trioleoylglycerol (TOG)	1435
K.6.1.13.4	Method Based on Radiolabeled Tributyrin	1435
K.6.1.13.5	Method Based on Resorufin Ester	1435
K.6.1.13.6	Method Based on p-Nitrophenylbutyrate	1436
K.6.1.13.7	Method Based on Potentiometry	1436
K.6.1.14	Neutral Cholesterylester Hydrolase Activity	1436
K.6.1.15	Lipoprotein Lipase (LPL) Activity	1436
K.6.1.16	Analysis of Lipolysis Products	1437
K.6.1.17	Affinity Labeling of TAG Lipases	1440
K.6.1.18	Interaction of ATGL and CGI-58	1442
K.6.1.19	Measurement of cAMP Levels	1443
K.6.1.20	cAMP-Specific Phosphodiesterase (PDE) Activity	1444
K.6.1.21	Activity State of Protein Kinase A (PKA)	1444
K.6.1.21.1	Radioactive Method	1444
K.6.1.21.2	Fluorescent Method	1445
K.6.1.22	PKA Catalytic Activity	1445
K.6.1.23	Protein Phosphatase (PP) Activity	1446
K.6.2	Assays for Insulin and Insulin- Like Metabolic Activity Based on Hepatocytes, Myocytes and Diaphragms	1447
K.6.2.1	Glucose Oxidation	1447
K.6.2.2	Pyruvate Oxidation	1447
K.6.2.3	Pyruvate Dehydrogenase Complex (PDC) Activity	1448
K.6.2.4	Pyruvate Dehydrogenase Kinase (PDK) Activity	1448
K.6.2.5	Fatty Acid Oxidation	1450
K.6.2.5.1	CO ₂ Release	1451
K.6.2.5.2	Release of Acid-Soluble Metabolites (ASM)	1452
K.6.2.6	Carnitine Palmitoyltransferase I (CPTI) Activity	1453

K.6.2.7	Respiratory Quotient (RQ)	1455
K.6.2.8	Phosphorylation of Acetyl-CoA Carboxylase (ACC) and AMP-Dependent Protein Kinase (AMPK)	1455
K.6.2.9	AMPK Activity	1456
K.6.2.9.1	Measurement with Recombinant AMPK	1457
K.6.2.9.2	Immunocomplex Kinase Assay	1459
K.6.2.9.3	Selectivity vs. Glycogen Phosphorylase (GP) and Fructose 1,6-bis-Phosphatase (FBP)	1460
K.6.2.9.4	AMP:ATP Levels	1460
K.6.2.9.5	Malonyl-CoA Levels	1461
K.6.2.10	Acetyl-CoA Carboxylase (ACC) Activity	1462
K.6.2.10.1	DTNB Method	1462
K.6.2.10.2	Phosphate Measurement	1463
K.6.2.11	Gluconeogenesis, Ketone Body Formation and TCA Cycle . .	1464
K.6.2.11.1	Hepatocytes	1465
K.6.2.11.2	Perfused Isolated Rat Liver	1465
K.6.2.11.3	Phosphoenolpyruvate Carboxy-kinase (PEPCK) Activity . . .	1466
K.6.2.12	Glucose Transport	1467
K.6.2.12.1	Method Based on Diaphragms	1467
K.6.2.12.2	Method Based on Myocytes	1467
K.6.2.12.3	GLUT4 Translocation in Myocytes	1468
K.6.2.13	Glycogen Synthesis	1470
K.6.2.13.1	Method Based on Diaphragms	1470
K.6.2.13.2	Method Based on Myotubes	1470
K.6.2.14	Glycogen Synthase (GS) Activity	1471
K.6.2.14.1	Method Based on Diaphragms	1471
K.6.2.14.2	Method Based on Myotubes/Hepatocytes	1472
K.6.2.15	Phosphorylation State of GS	1472
K.6.2.16	Protein Phosphatase 1G (PP1G) Activity and Phosphorylation	1473
K.6.2.17	Lipid Metabolism in Muscle and Liver Cells	1475
K.6.2.17.1	Incubation with Fatty Acids	1475
K.6.2.17.2	Lipid Synthesis	1476
K.6.2.17.3	Lipolysis	1477
K.6.2.18	Determination of Other Metabolites in Muscle	1480
K.6.3	Assays for Insulin and Insulin-Like Signal Transduction Based on Adipocytes, Hepatocytes and Myocytes	1481
K.6.3.1	Insulin Receptor (IR) Activation	1483
K.6.3.1.1	Insulin Binding	1484
K.6.3.1.2	IR Conformational Change Using BRET and FRET	1485
K.6.3.1.3	IR Tyrosine Phosphorylation	1487
K.6.3.2	Phosphorylation of Signaling Components by Insulin and Insulin-Like Stimuli	1493
K.6.3.2.1	Scintillation Proximity Assay (SPA)	1495
K.6.3.2.2	Fluorescence Polarization (FP) Assay	1495
K.6.3.2.3	Fluorescence-Based Assay	1495
K.6.3.2.4	Capillary Electrophoresis- Based Assay	1496
K.6.3.3	Dephosphorylation of Insulin and Insulin-Like Signaling Components	1497
K.6.3.3.1	Protein Tyrosine Phosphatase (PTP) Activity Measurement Using DIFMUP	1498
K.6.3.3.2	PTP Identification Using Substrate Trapping	1500
K.6.3.3.3	Lipid Phosphatase Activity Measurement	1501

K.6.3.3.4	Generic Assay for Protein Kinases (PK) and Phosphatases (PP) Based on Phosphate Release	1503
K.6.3.3.5	Cellular PTP Assays	1503
K.6.3.4	Expression, Phosphorylation, Activity and Interaction of Insulin Signaling Components	1510
K.6.3.4.1	Preparation of Cytosolic Extracts	1510
K.6.3.4.2	Immunoprecipitation	1511
K.6.3.4.3	Immunoblotting	1512
K.6.3.4.4	Immunocomplex Kinase Assay	1512
K.6.3.4.5	Phosphoproteomics	1515
K.6.3.4.6	Multiplex Bead Immunoassay	1516
K.6.3.4.7	Protein Interaction Analysis	1517
K.6.3.5	<i>O</i> -Linked Glycosylation (<i>O</i> -GlcNAc) of Insulin Signaling Components	1518
K.6.3.5.1	Induction of <i>O</i> -Glc-NAc Modification in Adipocytes, Myocytes and Muscles	1519
K.6.3.5.2	Assay for Glutamine/Fructose- 6-Phosphate Amidotransferase (GFAT)	1520
K.6.3.5.3	Assay for <i>O</i> -GlcNAc Transferase	1521
K.6.3.5.4	Measurement of GlcN-6-P Levels	1522
K.6.3.5.5	Measurement of UDP-GlcNAc Levels	1522
K.6.3.5.6	Detection of <i>O</i> -GlcNAc-Modified Proteins	1522
K.6.3.6	Insulin-Like Signal Transduction via Plasma Membrane Microdo- mains (Caveolae and Lipid Rafts)	1525
K.6.3.6.1	Preparation of Plasma Membranes	1527
K.6.3.6.2	Preparation of Lipid Rafts and Caveolae	1528
K.6.3.6.3	Lipid Raft- and Caveolae-Based Assays in Insulin and Insulin-Like Signal Transduction	1531
K.6.3.6.4	Glycosyl-Phosphatidylinositol-Specific Phospholipase (GPI-PL) and Insulin-Like Signaling	1536
K.6.4	Assays for Insulin and Insulin-Like Regulation of Gene and Protein Expression	1540
K.6.4.1	Protein Chips	1540
K.6.4.1.1	Challenges for Development	1541
K.6.4.1.2	Technologies	1541
K.6.4.2	DNA-Microarrays	1542
K.6.4.3	siRNA	1543
K.6.4.3.1	Design	1543
K.6.4.3.2	Source	1544
K.6.4.3.3	Delivery	1545
K.6.4.3.4	Use for Metabolic Diseases	1545
K.6.4.4	Effect on Peroxisome Proliferator-Activated Receptor	1546
K.6.4.4.1	Recombinant Cell Lines	1547
K.6.4.4.2	Lipogenesis Assay	1548
K.6.4.4.3	Protease Digestion Assay	1548
K.6.4.4.4	Living Cell Luciferase Assay	1548
K.6.4.4.5	Lysed Cell Luciferase Assay	1548
K.6.4.5	Effect on Proliferation	1550
K.6.5	Assays for Insulin and Insulin-Like Regulation of Energy Metabolism	1551
K.6.5.1	Determination of Oxygen Consumption and Extracellular Acidification Rates	1551
K.6.5.2	Metabolomics	1553

K.6.6	Assays for the Expression and Release of Insulin and Glucose-Regulating Peptide Hormones from Pancreatic β -Cells	1555
K.6.6.1	Insulin Release from the Isolated Perfused Rat Pancreas . . .	1555
K.6.6.2	Insulin Release from the Isolated Perfused Rat Pancreatic Islets	1556
K.6.6.3	Insulin Release from Cultured β -Cells	1556
K.6.6.4	Lipolysis in β -Cells	1557
K.6.6.5	Measurement of Ca^{2+} Levels	1559
K.6.6.6	Measurement of $^{86}\text{Rb}^{+}$ Efflux	1559
K.6.6.7	Measurement of Cell Membrane Potential	1560
K.6.6.8	Measurement of Mitochondrial Membrane Potential	1561
K.6.6.9	Measurement of cAMP Production	1561
K.6.6.10	Measurement of Cytosolic ATP Levels	1562
K.6.6.11	Analysis of Lipotoxicity	1562
K.6.6.12	Interaction with β -Cell Plasma Membranes and K_{ATP} Channels	1565
K.6.6.12.1	Isolation of Membranes	1565
K.6.6.12.2	Binding to Membranes	1566
K.6.6.12.3	Binding to Cells	1566
K.6.6.12.4	Photoaffinity Labeling of Membranes	1567
K.6.6.12.5	Binding to Recombinant SUR1	1568
K.6.6.12.6	Interaction with Extrapancreatic Tissues	1569
K.7	Measurement of Glucose Absorption	1571
K.7.1	Inhibition of Polysaccharide-Degrading Enzymes	1571
K.7.1.1	Assay for α -Amylase	1572
K.7.1.2	Assay for α -Glucosidase	1572
K.7.1.3	Everted Sac Technique for Assaying α -Glucosidase	1572
K.7.2	Assays for GLUT2 Transport Activity	1573
K.7.2.1	Perfusion of Jejunal Loops	1573
K.7.2.2	Transport Activity of Brush Border Membrane Vesicles	1575
K.7.2.3	Apical Expression of GLUT2	1576
K.7.3	Evaluation of Glucose Absorption In Vivo	1577
K.8	Monitoring of Diabetic Late Complications	1578
K.8.1	Aldose Reductase Activity	1578
K.8.1.1	Measurement with Normal Lenses	1579
K.8.1.2	Measurement w. Cataract Lenses	1579
K.8.2	Nerve Conduction Velocity	1581
K.8.3	Nerve Blood Flow (Doppler Flux)	1583
K.8.4	Electroretinogram	1583
K.8.5	Streptozotocin-Induced Cataract	1584
K.8.6	Naphthalene-Induced Cataract	1585
K.8.7	Determination of Advanced Glycation End Products (AGE) .	1585
K.8.8	Measurement of Reactive Oxygen Species (ROS) Production .	1589
K.9	Insulin Analogs: Assessment of Insulin Mitogenicity and IGF-I Activity	1592
K.9.1	Introduction and Application to Insulin Analogs	1592
K.9.2	Insulin Receptor Affinity	1594
K.9.3	Signaling Via Insulin Receptor	1596
K.9.4	IGF-I Receptor Affinity	1598
K.9.5	Signaling via IGF-1 Receptor	1599
K.9.6	Mitogenic Activity	1601
K.9.7	Insulin and IGF-1 Assays	1603
K.9.8	Assessment of Metabolic-Mitogenic Ratio In Vitro	1605

K.9.9	Assessment of Hypoglycemic Activity In Vivo	1605
K.9.9.1	Depot Activity of Insulin Analogs in Rabbits	1605
K.9.9.2	Depot Activity of Insulin Analogs in Fasted Dogs	1606
K.9.10	Mitogenic Risk and Safety Evaluation In Vivo	1607

Chapter L

Anti-obesity Activity 1609

L.1	Methods to Induce Experimental Obesity	1609
L.1.0.1	General Considerations	1609
L.1.0.2	Food-Induced Obesity	1610
L.1.0.3	Hypothalamic Obesity	1612
L.1.0.4	Goldthioglucose-Induced Obesity	1613
L.1.0.5	Monosodium Glutamate- Induced Obesity	1613
L.2	Genetically Obese Animals	1614
L.2.0.1	General Considerations	1614
L.2.0.2	Spontaneously Obese Rats	1614
L.2.0.3	Spontaneously Obese Mice	1617
L.2.0.4	Transgenic ANIMALS	1621
L.3	Assays of Anti-obesity Activity	1622
L.3.1	Anorectic Activity	1622
L.3.1.1	Food Consumption in Rats	1622
L.3.1.2	Computer-Assisted Measurement of Food Consumption in Rats	1625
L.3.1.3	The Endocannabinoid System	1625
L.3.2	Metabolic Activity	1629
L.3.2.1	GDP-Binding in Brown Adipose Tissue	1629
L.3.2.2	Uncoupling Protein and GLUT4 in Brown Adipose Tissue . .	1630
L.3.2.3	Resting Metabolic Rate	1633
L.3.2.4	β_3 -Adrenoceptor	1635
L.4	Assays of Obesity-Regulating Peptide Hormones	1636
L.4.0.1	Hormonal Regulation of Food Intake	1636
L.4.1	Leptin	1639
L.4.1.1	General Considerations on the Obese Gene Product Leptin . .	1639
L.4.1.2	Determination of Leptin mRNA Level in Adipose Tissue . . .	1641
L.4.1.3	Determination of Plasma Leptin	1642
L.4.2	Neuropeptide Y	1643
L.4.2.1	General Considerations on Neuropeptide Y and Related Peptides	1643
L.4.2.2	Receptor Assay of Neuropeptide Y	1645
L.4.3	Orexin	1650
L.4.3.1	General Considerations on Orexin	1650
L.4.3.2	Receptor Assay of Orexin	1651
L.4.3.3	Radioimmunoassay for Orexin	1652
L.4.4	Galanin	1652
L.4.4.1	General Considerations on Galanin	1652
L.4.4.2	Receptor Assay of Galanin	1655
L.4.5	Adipsin	1657
L.4.5.1	General Considerations on Adipsin	1657
L.4.5.2	Adipsin Expression in Mice	1658
L.4.6	Ghrelin	1659
L.5	Safety Pharmacology of Drugs with Anti-obesity Activity .	1660

Chapter M		
Anti-Atherosclerotic Activity		1661
M.1	Induction of Experimental Atherosclerosis	1662
M.1.0.1	General Considerations	1662
M.1.0.2	Cholesterol-Diet-Induced Atherosclerosis in Rabbits and Other Species	1662
M.1.0.3	Hereditary Hypercholesterolemia in Rats	1666
M.1.0.4	Hereditary Hyperlipemia in Rabbits	1666
M.1.0.5	Studies in Transgenic Mice	1667
M.1.0.6	Evaluation of Endothelial Function in Rabbits with Atherosclerosis	1668
M.1.0.7	Intimal Reactions After Endothelial Injury	1670
M.2	Influence on Lipid Metabolism	1671
M.2.0.1	General Considerations	1671
M.2.0.2	Hypolipidemic Activity in Rats	1672
M.2.0.3	Hypolipidemic Activity in Syrian Hamsters	1674
M.2.0.4	Triton-Induced Hyperlipidemia	1676
M.2.0.5	Fructose-Induced Hypertriglyceridemia in Rats	1677
M.2.0.6	Intravenous Lipid Tolerance Test in Rats	1677
M.2.0.7	Influence on Lipoprotein- Lipase Activity	1678
M.2.0.8	Influence on Several Steps of Cholesterol Absorption and Formation	1678
M.3	Inhibition of Cholesterol Biosynthesis	1682
M.3.1	General Considerations on Cholesterol Biosynthesis	1682
M.3.2	Determination of HMG-CoA-Reductase Inhibitory Activity	1683
M.3.2.1	General Considerations on HMG-CoA-Reductase	1683
M.3.2.2	Inhibition of the Isolated Enzyme HMG-CoA-Reductase in Vitro	1684
M.3.2.3	Inhibition of the Incorporation of ¹⁴ C-Sodium Acetate into Cholesterol in Isolated Liver Cells	1685
M.3.2.4	Ex Vivo Inhibition of Cholesterol Biosynthesis in Isolated Rat Liver Slices	1686
M.3.2.5	Effect of HMG-CoA-Reductase Inhibitors in Vivo	1687
M.3.2.6	Influence of Statins on Endothelial Nitric Oxide Synthase	1689
M.3.3	Inhibition of Squalene Synthase	1691
M.3.4	Inhibition of Squalene Epoxidase	1693
M.4	Inhibition of Cholesterol Absorption	1694
M.4.1	Inhibition of ACAT (Acyl Coenzyme A: Cholesterol Acyltransferase)	1694
M.4.1.1	General Considerations	1694
M.4.1.2	In Vitro ACAT Inhibitory Activity	1695
M.4.1.3	In Vivo Tests for ACAT Inhibitory Activity	1696
M.4.1.4	Lymph Fistula Model for Cholesterol Absorption	1697
M.5	Interruption of Bile Acid Recirculation	1698
M.5.0.1	Cholestyramine Binding	1698
M.6	Inhibition of Lipid Oxidation	1699
M.6.0.1	General Considerations	1699
M.6.0.2	Inhibition of Lipid Peroxidation of Isolated Plasma Low-Density Lipoproteins	1699
M.7	Internalization of Labeled LDL into HepG2 Cells	1701

M.8	Influence of Peroxisome Proliferator-Activated Receptors (PPARs) and Liver X Receptors (LXRs) on Development of Atherosclerosis	1701
M.8.1	General Considerations	1701
M.8.2	Influence of PPAR Activation	1702
M.8.2.1	PPAR α	1702
M.8.2.1.1	Effect of PPAR α Agonists in Mice	1703
M.8.2.1.2	Effect of PPAR α and PPAR γ Agonists in Human Macrophages	1704
M.8.2.2	PPAR γ	1706
M.8.2.2.1	Effect of PPAR γ Agonists in Mice	1706
M.8.2.2.2	Effect of PPAR γ Agonists on Gene Expression in Macrophages	1708
M.8.2.3	PPAR δ	1709
M.8.3	Influence of Liver X Receptor Agonists	1711
M.8.3.1	Stimulation of Cholesterol Efflux	1712
M.8.3.2	Liver X Receptor Binding	1714
M.8.3.3	Inhibition of Atherosclerosis by LXR Ligands	1715
M.9	Safety Pharmacology of Anti-Atherosclerotic Drugs	1717
Chapter N		
Endocrinology		1719
N.1	Preface	1723
N.1.1	Endocrine Survey	1723
N.2	Adrenal Steroid Hormones	1724
N.2.0.1	Adrenalectomy in Rats	1724
N.2.1	Glucocorticoid Activity	1725
N.2.1.1	In Vitro Methods for Glucocorticoid Hormones	1725
N.2.1.1.1	Corticoid Receptor Binding	1725
N.2.1.1.2	Transactivation and Transrepression Assays for Glucocorticoids	1727
N.2.1.1.3	Induction of Tyrosine Aminotransferase (TAT) Hepatoma Cells	1731
N.2.1.1.4	Effect on T-Lymphocytes	1732
N.2.1.1.5	Inhibition of Cartilage Degradation	1733
N.2.1.2	In Vivo Methods for Glucocorticoid Hormones	1734
N.2.1.2.1	General Considerations	1734
N.2.1.2.2	Adrenal and Thymus Involution	1734
N.2.1.2.3	Eosinopenia in Adrenalectomized Mice	1734
N.2.1.2.4	Liver Glycogen Test in Rats	1735
N.2.1.2.5	Anti-Inflammatory Activity of Corticoid Hormones	1736
N.2.1.2.6	Animal Studies for Corticoid Hormone Evaluation	1736
N.2.1.3	Effects of Steroids on Mechanical Properties of Connective Tissue	1738
N.2.1.3.1	Breaking Strength of Bones	1738
N.2.1.3.2	Tensile Strength of Femoral Epiphyseal Cartilage in Rats	1739
N.2.1.3.3	Tensile Strength of Tail Tendons in Rats	1739
N.2.1.3.4	Tensile Strength of Skin Strips in Rats	1740
N.2.1.4	Topical Effects of Glucocorticosteroids on Skin	1741
N.2.1.4.1	Skin Thickness and Tensile Strength	1741

N.2.1.4.2	Assay of Topical Glucocorticoid Activity in Transgenic Mice	1743
N.2.1.4.3	Effect on Epidermal DNA Synthesis	1744
N.2.1.4.4	Induction of Drug-Metabolizing Enzymes	1745
N.2.1.4.5	Cornea Inflammation in Rabbits	1745
N.2.1.4.6	Endotoxin-Induced Uveitis in Rats	1746
N.2.1.4.7	Croton Oil-Induced Ear Inflammation	1746
N.2.1.5	Anti-Glucocorticoid Activity	1746
N.2.1.5.1	Adrenal and Thymus Involution	1746
N.2.2	Mineralocorticoid Activity	1747
N.2.2.1	In Vivo Methods	1747
N.2.2.1.1	General Considerations	1747
N.2.2.1.2	Electrolyte Excretion	1747
N.2.2.2	In Vitro Methods	1748
N.2.2.2.1	Mineralocorticoid Receptor Binding	1748
N.2.2.2.2	Transactivation Assay for Mineralocorticoids	1750
N.2.2.3	Anti-Mineralocorticoid Activity	1751
N.2.2.3.1	Electrolyte Excretion	1751
N.3	Ovarian Hormones	1753
N.3.0.1	Ovariectomy of Rats	1753
N.3.1	Estrogens	1753
N.3.1.1	In Vitro Methods	1753
N.3.1.1.1	Estrogen Receptor Binding	1753
N.3.1.1.2	Transactivation Assay for Estrogens	1755
N.3.1.1.3	Estrogen-Dependent Cell Proliferation	1757
N.3.1.2	In Vivo Methods	1758
N.3.1.2.1	Vaginal Cornification Assay	1758
N.3.1.2.2	Uterine Weight Assay	1759
N.3.1.2.3	Chick Oviduct Method	1759
N.3.1.3	Anti-Estrogenic Activity	1760
N.3.1.3.1	Antagonism of Estrogen Effect on Uterus Weight	1760
N.3.1.3.2	Aromatase Inhibition	1761
N.3.1.3.3	Anti-Estrogenic Effect on MCF-7 Breast Cancer Cells	1762
N.3.2	Progestational Activity	1763
N.3.2.1	In Vitro Methods	1763
N.3.2.1.1	Gestagen Receptor Binding	1763
N.3.2.1.2	Transactivation Assay for Gestagens	1765
N.3.2.1.3	Alkaline Phosphatase Assay	1766
N.3.2.2	In Vivo Methods	1767
N.3.2.2.1	Clauberg (McPhail) Test in Rabbits	1767
N.3.2.2.2	Endometrial Carbonic Anhydrase Assay	1768
N.3.2.2.3	Deciduoma Formation	1768
N.3.2.2.4	Pregnancy Maintenance Assay	1769
N.3.2.3	Anti-Progestational Activity	1769
N.3.2.3.1	Progesterone Antagonism (Anti-Progestins)	1769
N.3.2.3.2	Luteolytic Activity of Prostaglandins	1770
N.4	Testicular Steroid Hormones	1772
N.4.0.1	Castration of Male Rats (Orchiectomy)	1772
N.4.0.2	Caponizing of Cockerels (Orchiectomy)	1772
N.4.1	Androgenic and Anabolic Activity	1772
N.4.1.1	In Vitro Methods	1772
N.4.1.1.1	Androgen Receptor Binding	1772
N.4.1.1.2	Transactivation Assay for Androgens	1774

N.4.1.2	In Vivo Methods	1776
N.4.1.2.1	Chicken Comb Method for Androgen Activity	1776
N.4.1.2.2	Weight of Androgen-Dependent Organs in Rats	1777
N.4.1.2.3	Nitrogen Retention	1778
N.4.2	Anti-Androgenic Activity	1778
N.4.2.0.1	General Considerations	1778
N.4.2.1	In Vitro Methods	1779
N.4.2.1.1	Inhibition of 5 α -Reductase	1779
N.4.2.2	In Vivo Methods	1780
N.4.2.2.1	Chick Comb Method	1780
N.4.2.2.2	Antagonism of Androgen Action in Castrated Rats	1781
N.4.2.2.3	Anti-Androgenic Activity in Female Rats	1782
N.4.2.2.4	Intra-Uterine Feminizing/Virilizing Effect	1782
N.4.2.2.5	Anti-Androgenic Activity on Sebaceous Glands	1783
N.4.2.2.6	Anti-Androgenic Activity in the Hamster Flank Organ	1783
N.4.2.2.7	Effect of 5 α -Reductase Inhibitors on Plasma and Tissue Steroid Levels	1784
N.5	Thyroid Hormones	1784
N.5.0.1	General Considerations	1784
N.5.0.2	Thyroidectomy	1786
N.5.1	In Vivo Tests for Thyroid Hormones	1787
N.5.1.1	Oxygen Consumption	1787
N.5.1.2	Inhibition of Iodine Release	1788
N.5.1.3	Anti-Goitrogenic Activity	1788
N.5.1.4	Tensile Strength of Connective Tissue in Rats, Modified for Thyroid Hormones	1789
N.5.2	Antithyroid Drugs	1790
N.5.2.1	General Considerations	1790
N.5.2.2	Inhibition of Iodine Uptake in Rats	1790
N.5.2.3	Antithyroidal Effects in Animal Assays	1791
N.5.3	Calcitonin	1791
N.5.3.1	General Considerations	1791
N.5.3.2	Decrease of Serum Calcium in Rats	1792
N.5.3.3	Effect of Calcitonin on Osteoclasts in Vitro	1793
N.5.3.4	Receptor Binding and cAMP Accumulation in Isolated Cells	1794
N.6	Parathyroid Hormone	1796
N.6.0.1	General Considerations	1796
N.6.0.2	Receptor Binding Assay for PTH	1797
N.6.0.3	PTH Assay by Serum Calcium Increase	1798
N.6.0.4	Serum Phosphate Decrease After PTH	1799
N.6.0.5	cAMP Release in Isolated Perfused Rat Femur	1799
N.6.0.6	Renal and Metatarsal Cytochemical Bioassay	1800
N.6.0.7	cAMP Accumulation in Cultured Cells	1801
N.6.0.8	Bone Anabolic Activity in Ovariectomized, Osteopenic Rats	1802
N.7	Anterior Pituitary Hormones	1803
N.7.0.1	Hypophysectomy in Rats	1804
N.7.1	Gonadotropins	1805
N.7.1.0.1	General Considerations	1805
N.7.1.1	Follicle-Stimulating Hormone (FSH)	1806
N.7.1.1.1	Ovarian Weight in hCG-Primed Rats	1806
N.7.1.1.2	[³ H]Thymidine Uptake in Cultured Mouse Ovaries	1807

N.7.1.1.3	Granulosa Cell Aromatase Assay in Vitro	1807
N.7.1.1.4	Sertoli Cell Aromatase Assay in Vitro	1809
N.7.1.1.5	Receptor Binding Assay for FSH	1810
N.7.1.2	Luteinizing Hormone (LH) = Interstitial Cell Stimulating Hormone (ICSH)	1811
N.7.1.2.1	Prostate Weight in Hypophysectomized Rats	1811
N.7.1.2.2	Superovulation in Immature Rats	1812
N.7.1.2.3	Ascorbic Acid Depletion of Ovaries in PMSG/hCG-Primed Rats	1812
N.7.1.2.4	Testosterone Production by Leydig Cells in Vitro Induced by LH	1813
N.7.1.2.5	Receptor Binding Assay for LH	1814
N.7.1.3	Other Gonadotropins	1815
N.7.1.3.1	Corpus Luteum Formation in Immature Mice (Aschheim-Zondek Test)	1815
N.7.1.3.2	Biological Assay of hCG in Immature Male Rats	1815
N.7.1.3.3	Receptor Binding Assay for hCG	1816
N.7.1.4	Human Menopausal Gonadotropin (hMG)	1817
N.7.1.4.1	Biological Assay of hMG in Immature Rats	1817
N.7.1.5	Pregnant Mares' Serum Gonadotropin (PMSG)	1817
N.7.1.5.1	Biological Assay of PMSG in Immature Female Rats	1817
N.7.1.6	Immunoassays of Gonadotropins	1817
N.7.1.7	Gonadotropin inhibition	1818
N.7.1.7.1	General Considerations	1818
N.7.1.7.2	Inhibition of Gonadotropin Secretion in Intact Animals	1818
N.7.1.7.3	Inhibition of Ovulation and Luteinization	1819
N.7.1.7.4	Ovary-Spleen Transplantation	1820
N.7.1.7.5	Inhibition of Fertility	1820
N.7.2	Prolactin	1821
N.7.2.1	General Considerations	1821
N.7.2.2	Radioimmunoassay of Rat Prolactin	1821
N.7.2.3	Pigeon Crop Method	1822
N.7.2.4	Lactation in Rabbits	1822
N.7.3	Growth hormone (GH)	1823
N.7.3.1	General Considerations	1823
N.7.3.2	Weight Gain in Female Rats ("Growth Plateau Rats")	1824
N.7.3.3	Tibia Test in Hypophysectomized Rats	1825
N.7.3.4	³⁵ S Uptake	1825
N.7.3.5	Inhibition of Glucose Uptake in Adipocytes in Vitro	1826
N.7.3.6	Eluted Stain Bioassay for Human Growth Hormone	1826
N.7.3.7	Reverse Hemolytic Plaque Assay for Growth Hormone	1827
N.7.3.8	Determination of Growth Hormone Isoforms by 22-kDa GH Exclusion Assay	1828
N.7.3.9	Steroid Regulation of Growth Hormone Receptor and GH-Binding Protein	1829
N.7.4	Adrenocorticotropin (ACTH)	1830
N.7.4.1	Adrenal Ascorbic Acid Depletion	1830
N.7.4.2	Corticosterone Blood Levels in Dexamethasone-Blocked Rats	1832
N.7.4.3	In Vitro Corticosteroid Release	1833
N.7.4.4	Thymus Involution	1834
N.7.4.5	Receptor Binding Assay for ACTH	1835

N.7.5	Thyrotropin (TSH)	1836
N.7.5.1	General Considerations	1836
N.7.5.2	Thyroid Histology	1836
N.7.5.3	Iodine Uptake	1837
N.7.5.4	TSH Bioassay Based on cAMP Accumulation in CHO Cells	1837
N.7.6	Hormones Related to TSH	1838
N.7.6.1	General Considerations	1838
N.7.6.2	Assay of Exophthalmos-Producing Substance (EPS) in Fishes	1838
N.7.6.3	Assay of Long-Acting Thyroid-Stimulating Factor (LATS) in Mice	1839
N.8	Posterior Pituitary Hormones	1840
N.8.0.1	General Considerations	1840
N.8.1	Oxytocin	1841
N.8.1.1	Isolated Uterus	1841
N.8.1.2	Chicken Blood Pressure	1842
N.8.1.3	Milk Ejection in the Lactating Rabbit or Rat	1843
N.8.1.4	Oxytocin Receptor Determination	1844
N.8.2	Vasopressin	1845
N.8.2.1	Hereditary Vasopressin Deficiency in Rats (Brattleboro Strain)	1845
N.8.2.2	Vasopressor Activity	1846
N.8.2.3	Antidiuretic Activity in the Conscious Rat	1847
N.8.2.4	Antidiuretic Activity in the Rat in Ethanol Anesthesia	1848
N.8.2.5	Spasmogenic Activity of Vasopressin in the Isolated Guinea Pig Ileum	1849
N.8.2.6	Vasopressin Receptor Determination	1849
N.9	Hypothalamic Hormones	1852
N.9.1	Thyrotropin-Releasing Hormone (TRH)	1852
N.9.1.1	General Considerations	1852
N.9.1.2	TRH Receptor Binding Assays	1853
N.9.1.3	Release of ¹³¹ I from Thyroid Glands of Mice	1854
N.9.1.4	Release of TSH from Rat Anterior Pituitary Glands in Vitro	1855
N.9.1.5	TSH and Prolactin Release by TRH in Rats	1856
N.9.2	Luteinizing Hormone Releasing Hormone (LH-RH)	1856
N.9.2.1	General Considerations	1856
N.9.2.2	LH-RH Receptor Assays	1857
N.9.2.3	LH Release in the Ovariectomized Estrogen-Progesterone-Blocked Rat	1859
N.9.2.4	Gonadotropin Release From Anterior Pituitary Cells	1861
N.9.2.5	Radioimmunoassay of Rat LH	1862
N.9.2.6	Radioimmunoassay of Rat Follicle-Stimulating Hormone (FSH)	1862
N.9.2.7	Measurement of Ascorbic Acid Depletion in Ovaries of Pseudopregnant Rats	1863
N.9.2.8	Progesterone Production in Pseudopregnant Rats	1864
N.9.2.9	Induction of Ovulation in Rabbits	1864
N.9.2.10	Induction of Superovulation in Immature Rats	1865
N.9.2.11	Inhibition of Experimentally Induced Endometriosis	1865
N.9.3	LH-RH Antagonistic Activity	1866
N.9.3.1	Testosterone Suppression in Rats	1866
N.9.3.2	Antiovarulatory Activity in Rats	1867

N.9.3.3	Effect of Repeated Administration of LH-RH Antagonists in Rats	1868
N.9.3.4	Inhibition of Gonadotropin Release From Anterior Pituitary Cultures	1869
N.9.3.5	Anti-Tumor Effect of LH-RH Antagonists	1870
N.9.4	Corticotropin-Releasing Hormone (CRH)	1871
N.9.4.1	General Considerations	1871
N.9.4.1.1	Central Effects and Actions of CRH	1873
N.9.4.2	In Vitro Assay for CRH Activity	1874
N.9.4.3	In Vivo Bioassay of CRH Activity	1875
N.9.4.4	Collection of Hypophyseal Portal Blood in Rats	1875
N.9.4.5	CRH Receptor Determination	1876
N.9.4.6	CRF Receptor Antagonists	1879
N.9.5	Growth-Hormone-Releasing Hormone (GH-RH)	1880
N.9.5.1	General Considerations	1880
N.9.5.2	Radioreceptor Assay of Growth Hormone-Releasing Hormone	1881
N.9.5.2.1	Growth Hormone Release from Rat Pituitaries in Vitro	1883
N.9.5.2.2	Long-Term Pituitary Cell Culture	1884
N.9.5.3	GH-RH Bioassay by Growth Hormone Release in Rats	1885
N.9.5.4	GH-RH Analogs	1885
N.10	Other Peptide Hormones	1886
N.10.1	Melatonin	1886
N.10.1.1	General Considerations	1886
N.10.1.2	Melatonin Receptor Binding	1886
N.10.1.3	In Vitro Assay of Melatonin: Inhibition of Forskolin-Stimulated cAMP Accumulation	1888
N.10.1.4	Dopamine Release from Rabbit Retina	1889
N.10.1.5	Effect on Xenopus Melanophores	1889
N.10.1.6	Vasoconstrictor Activity of Melatonin	1890
N.10.1.7	Melatonin's Effect on Firing Rate of Suprachiasmatic Nucleus Cells	1891
N.10.1.8	Melatonin's Effect on Circadian Rhythm	1892
N.10.1.9	Melatonin's Effect on Neophobia in Mice	1893
N.10.2	Melanophore Stimulating Hormone	1894
N.10.2.1	Skin Darkening in Whole Amphibia	1894
N.10.2.2	Assay in Isolated Amphibian Skin	1895
N.10.2.3	Binding to the Melanocortin Receptor	1896
N.10.3	Melanocortin Peptides	1898
N.10.4	Relaxin	1899
N.10.4.1	General Considerations	1899
N.10.4.2	Relaxin Bioassay by Pubic Symphysis Method in Guinea Pigs	1900
N.10.4.3	Relaxin Bioassay in Mice	1901
N.10.4.4	Inhibition of Uterine Motility	1901
N.10.4.5	Relaxin Assay by Interstitial Collagenase Activity in Cultured Uterine Cervical Cells	1902
N.10.4.6	Relaxin Receptor Binding	1903
N.10.5	Calcitonin Gene-Related Peptide	1904
N.10.5.1	General Considerations	1904
N.10.5.2	Receptor Binding of CGRP	1907
N.10.6	Inhibin	1908
N.10.6.1	General Considerations	1908

N.10.6.2	In Vitro Bioassay for Inhibin	1909
N.10.7	Activin	1911
N.10.7.1	General Considerations	1911
N.10.7.2	In Vitro Bioassay for Activin	1912
N.10.8	Follistatin	1914
N.10.8.1	General Considerations	1914
N.10.8.2	Immunoassay for Follistatin	1914
N.10.9	Further Peptide Hormones Discussed in Chapters Related to the Respective Indications	1915

Chapter O

Ophthalmologic Activity 1917

O.1	Introduction	1917
O.2	Intraocular Pressure	1917
O.2.1	Acute Measurement of Intraocular Pressure	1917
O.2.2	Measurement of Intraocular Pressure by Telemetry	1920
O.3	Aqueous Humor Flow Rate	1921
O.4	Experimental Glaucoma	1922
O.4.1	Alpha-Chymotrypsin Induced Glaucoma in Rabbits	1922
O.4.2	Episcleral Venous Occlusion Induced Glaucoma in Rats	1924
O.4.3	Photocoagulation Induced Glaucoma in Monkeys	1925
O.5	Local Anesthesia of the Cornea	1925
O.6	Experimental Cataract Formation	1926
O.6.1	N-Methyl-N-Nitrosourea Cataract Induction Sprague-Dawley Rats	1927
O.6.2	TGF β Cataract Induction in Wistar Rats	1930
O.6.3	Diabetic Cataract Formation in Sprague Dawley Rats	1931
O.6.4	Cataract Formation in Knock Out Mice	1932
O.7	Models of Eye Inflammation	1933
O.7.1	Allergic Conjunctivitis	1933
O.7.2	Corneal Inflammation	1934
O.7.3	Auto-Immune Uveitis in Rats	1935
O.7.4	Ocular Inflammation Induced by Paracentesis	1937
O.7.5	Ocular Inflammation by Lens Proteins	1938
O.7.6	Proliferative Vitreoretinopathy in Rabbits	1938
O.8	Safety Pharmacology of Drugs with Ophthalmologic Activity	1939

Chapter P

Pharmacological Models in Dermatology 1941

P.1	Skin Sensitization Testing	1942
P.1.1	Guinea Pig Maximization Assay	1942
P.1.2	Popliteal Lymph Node Hyperplasia Assay	1944
P.1.3	Local Lymph Node Assay	1944
P.2	Experimental Dermatitis	1945
P.2.1	Spontaneous Dermatitis	1945
P.2.1.1	NC/Nga Mouse as Model for Atopic Dermatitis	1945
P.2.1.2	Moth-eaten Mice	1947
P.2.1.3	Spontaneous Erythema in Hairless Rats	1947
P.2.1.4	Spontaneous Atopic Dermatitis in Dogs	1948

P.2.2	Contact Dermatitis	1948
P.2.2.1	Contact Hypersensitivity in Animals	1948
P.2.2.1.1	Contact Hypersensitivity in Mice	1948
P.2.2.1.2	Contact Hypersensitivity in Rats	1950
P.2.2.1.3	Contact Hypersensitivity in Guinea Pigs	1950
P.2.2.1.4	Contact Hypersensitivity in Pigs	1950
P.2.2.2	Non-Immunologic Contact Urticaria	1952
P.2.3	Immunological Models of Atopic Dermatitis	1953
P.2.3.1	Mononuclear Cells from Atopic Dermatitis Donors	1953
P.2.3.2	The SCID-hu Skin Mouse as Model for Atopic Dermatitis	1953
P.3	Pruritus Models	1956
P.3.1	Pruritus and Scratching Behavior in Mice	1956
P.3.2	Pruritic Dermatitis in Other Species	1958
P.4	Psoriasis Models	1959
P.4.1	General Considerations	1959
P.4.2	In Vitro Studies with Isolated Cells	1959
P.4.2.1	Cultured Keratinocytes	1959
P.4.2.2	Effect on T Lymphocytes	1962
P.4.3	Psoriasis Models in Normal Animals	1964
P.4.3.1	Mouse Tail Model for Psoriasis	1964
P.4.3.2	Rat Ultraviolet Ray B Photodermatitis Model for Psoriasis	1965
P.4.4	Hyperproliferative Epidermis in Hairless Mice	1966
P.4.5	Psoriasisiform Skin Diseases in Spontaneous Mice Mutations	1967
P.4.5.1	Flaky Skin (<i>fsn</i>) Mouse	1967
P.4.5.2	Asebia (<i>ab/ab</i>) Mouse	1968
P.4.6	Psoriasisiform Skin Diseases in Genetically Modified Animals	1969
P.4.7	Xenotransplantation of Human Psoriatic Skin	1971
P.5	Scleroderma Models	1973
P.5.1	Scleroderma Models in Chicken	1973
P.5.2	Scleroderma Models in Mice	1974
P.6	Pemphigus Models	1975
P.6.1	Experimentally Induced Pemphigus in Mice	1975
P.7	Ichthyosis Vulgaris Models	1977
P.7.1	Experimentally Induced Ichthyosis in Mice	1977
P.8	Xeroderma Models	1978
P.8.1	Experimentally Induced Xeroderma in Mice	1978
P.9	Vitiligo Models	1979
P.9.1	Vitiligo in Mice	1979
P.9.2	Smyth Line Chickens	1979
P.10	Erythropoietic Protoporphyrria	1980
P.10.1	General Considerations	1980
P.10.2	Animal Models for Erythropoietic Protoporphyrria	1980
P.11	Acne Models	1982
P.11.1	Activity on Sebaceous Glands of Rats	1982
P.11.2	Activity on Sebaceous Glands of the Fuzzy Rat	1983
P.11.3	Activity on Ear Sebaceous Glands of Syrian Hamsters	1985
P.11.4	Activity on Ear Sebaceous Glands of Rabbits	1986
P.11.5	Activity on the Hamster Flank Organ	1986
P.11.6	Activity on the Skin of the Rhino Mouse	1988
P.11.7	Activity on the Skin of the Mexican Hairless Dog	1990
P.11.8	In Vitro Sebocyte Model	1990

P.12	Skin Mycosis	1992
P.12.1	General Considerations	1992
P.12.2	In Vitro Inhibitory Activity	1992
P.12.3	In Vivo Activity in the Guinea Pig Trichophytosis Model	1993
P.12.4	Skin Penetration	1993
P.13	Biomechanics of Skin	1994
P.13.1	General Considerations	1994
P.13.2	In Vitro (ex Vivo) Experiments	1995
P.13.2.1	Stress-Strain Behavior	1995
P.13.2.1.1	Measurement of Skin Thickness, Ultimate Load, Tensile Strength, Ultimate Strain and Modulus of Elasticity	1995
P.13.2.1.2	Measurement of Mechanical Properties at Low Extension Degrees	1998
P.13.2.1.3	Step Phenomenon	1998
P.13.2.1.4	Anisotropy of Skin	1999
P.13.2.1.5	Relaxation Phenomenon	2000
P.13.2.1.6	Hysteresis Experiments	2001
P.13.2.1.7	Isorheological Point	2002
P.13.2.1.8	Creep Experiments	2003
P.13.2.1.9	Repeated Strain	2003
P.13.2.1.10	Correlation Between Biomechanical and Biochemical Parameters	2004
P.13.2.2	Thermocontraction	2005
P.13.3	In Vivo Experiments	2006
P.13.3.1	Stress-Strain Curves in Vivo	2006
P.13.3.2	Repeated Strain in Vivo	2008
P.13.3.3	In Vivo Recovery After Repeated Strain	2008
P.13.4	Healing of Skin Wounds	2009
P.14	Protection Against UV Light	2012
P.15	Transepidermal Water Loss (TEWL)	2013
P.16	Skin Hydration	2014
P.17	Influence on Hair Growth	2015
P.18	Cutaneous Microcirculation	2017
P.18.1	General Considerations	2017
P.18.2	Laser Doppler Velocimetry	2017
P.18.3	Measurement of Skin Microcirculation by Reflectance Spectroscopy	2018
P.19	Isolated Perfused Skin Flap	2019
P.20	Safety Assays in Skin Pharmacology	2021

Chapter Q

Guidelines for the Care and Use of Laboratory Animals 2023

Q.1	Regulations for the Care and Use of Laboratory Animals in Various Countries	2023
Q.2	Techniques of Blood Collection in Laboratory Animals	2023
Q.2.1	Introduction	2023
Q.2.2	Aspects of Animal Welfare	2026
Q.2.3	Total Blood Volume	2026
Q.2.4	Terminal Blood Collection	2026
Q.2.5	Non-terminal Blood Collection	2027
Q.2.5.1	Single Blood Removal	2027

Q.2.5.2	Multiple Blood Removal	2027
Q.2.6	Technical Aspects of Blood Removal	2028
Q.2.6.1	Permanent Venous Cannulation	2028
Q.2.6.2	Retro-Orbital Bleeding	2028
Q.2.6.3	Cardiac Puncture	2029
Q.3	Anesthesia of Experimental Animals	2029
Q.3.1	Introduction	2029
Q.3.2	Local Anesthesia	2030
Q.3.3	General Anesthesia	2030
Q.3.3.1	Preparation	2030
Q.3.3.2	Premedication	2030
Q.3.3.2.1	Hydration and Base Excess	2030
Q.3.3.2.2	Atropine	2030
Q.3.3.2.3	Sedation and Pain Elimination	2030
Q.3.3.3	Course of Anesthesia	2032
Q.3.3.4	Routes of General Anesthesia	2032
Q.3.3.4.1	Injection	2032
Q.3.3.4.2	Inhalation	2033
Q.3.3.4.3	Inhalation Compounds	2034
Q.3.3.5	Termination of Anesthesia	2034
Q.3.4	Postoperative Analgesia	2034
Q.4	Euthanasia of Experimental Animals	2035
Q.4.1	Introduction	2035
Q.4.2	Euthanasia	2035
Q.4.2.1	Physical Methods Recommended for Euthanasia of Laboratory Animals	2035
Q.4.2.2	Chemical Agents Recommended for Euthanasia of Laboratory Animals	2036
Q.4.2.3	Methods and Agents Not to Be Used for Euthanasia of Laboratory Animals	2036
Q.4.2.4	Recommended Methods for Euthanasia for Specific Animal Species	2036
Index		2039

Contributors

Editor

Prof. emer. Dr. Dr. H. Gerhard Vogel,
Johann Wolfgang Goethe Universität,
Frankfurt,
Germany

Contributors to the third edition

Albus, Udo,
Sanofi-Aventis Pharma Research,
65926 Frankfurt,
Germany

Bickel, Martin,
Sanofi-Aventis Pharma Research,
Metabolism Research,
65926 Frankfurt,
Germany

Gögelein, Heinz,
Sanofi-Aventis Pharma Research,
Cardiovascular Research,
65926 Frankfurt,
Germany

Hart, Susan G. Emeigh,
Genaera Corporation,
5110 Campus Drive Plymouth Meeting,
PA 19462,
USA

Herling, Andreas W.,
Sanofi-Aventis Pharma Research,
Metabolism Research,
65926 Frankfurt,
Germany

Huwiler, Andrea,
Institute of Pharmacology University of Bern,
Friedbühlstrasse 49,
3010 Bern,
Switzerland

Juretschke, Paul,
Sanofi-Aventis Pharma Research,
65926 Frankfurt,
Germany

Mousa, Shaker A.,
The Pharmaceutical Research Institute at Albany,
Albany College of Pharmacy,
106 New Scotland Avenue,
Albany,
NY 12208,
USA

Müller, Günter,
Sanofi-Aventis Pharma Research,
Metabolism Research,
65926 Frankfurt,
Germany

Sandow, Jürgen,
Sanofi-Aventis Pharma Research,
Metabolism Research,
65926 Frankfurt,
Germany

Schäfer, Hans-Ludwig,
Sanofi-Aventis Pharma Research,
Metabolism Research,
65926 Frankfurt,
Germany

Schultz, Beth,
College of Optometry Philadelphia,
60 Tennis Ave Ambler,
PA 19002,
USA

Vogel, Wolfgang F.,
Department of Laboratory Medicine and Pathobiology,
Faculty of Medicine,
University of Toronto,
Canada

Vogel, Wolfgang H.,
Jefferson Medical College,
Thomas Jefferson University,
Department of Pharmacology,
Philadelphia,
USA

Wirth, Klaus J.,
Sanofi-Aventis Pharma Research,
Cardiovascular Research,
65926 Frankfurt,
Germany

Contributors to the second edition

Albus, Udo,
Aventis Pharma Research,
65926 Frankfurt,
Germany

Bickel, Martin,
Aventis Pharma Research,
Metabolism Research,
65926 Frankfurt,
Germany

Bleich, Markus,
Aventis Pharma Research,
Cardiovascular Research,
65926 Frankfurt,
Germany

Dere, Ekrem,
Institute of Physiological Psychology,
Heinrich Heine Universität Düsseldorf,
Germany

Gögelein, Heinz,
Aventis Pharma Research,
Cardiovascular Research,
65926 Frankfurt,
Germany

Herling, Andreas W.,
Aventis Pharma Research,
Metabolism Research,
65926 Frankfurt,
Germany

Hropot, Max,
Aventis Pharma Research,
Cardiovascular Research,
65926 Frankfurt,
Germany

Laux, Volker,
Aventis Pharma Research,
Cardiovascular Research,
65926 Frankfurt,
Germany

Just, Melitta,
Aventis Pharma Research,
Cardiovascular Research,
65926 Frankfurt,
Germany

Müller, Günter,
Aventis Pharma Research,
Metabolism Research,
65926 Frankfurt,
Germany

Rieß, Günther,
Aventis Pharma Research,
65926 Frankfurt,
Germany

Sadow, Jürgen,
Aventis Pharma Research,
Metabolism Research,
65926 Frankfurt,
Germany

Schäfer, Hans-Ludwig,
Aventis Pharma Research,
Metabolism Research,
65926 Frankfurt,
Germany

Vogel, Wolfgang F.,
Assistant Professor,
Department of Laboratory Medicine and Pathobiology,
Faculty of Medicine,
University of Toronto,
Canada

Vogel, Wolfgang H.,
Jefferson Medical College,
Thomas Jefferson University,
Department of Pharmacology,
Philadelphia,
USA

Wirth, Klaus J.,
Aventis Pharma Research,
Cardiovascular Research,
65926 Frankfurt,
Germany

Contributors to the first edition**Albus, Udo,**

Hoechst-Marion-Roussel,
Cardiovascular Research,
65926 Frankfurt,
Germany

Bartlett, Robert R.,

Hoechst-Marion-Roussel,
Immunopharmacology,
65174 Wiesbaden,
Germany

Bickel, Martin,

Hoechst-Marion-Roussel,
Metabolism Research,
65926 Frankfurt,
Germany

Brioni, Jorge D.,

Abbott Laboratories,
Neuroscience Research,
Abbott Park,
IL 60064,
USA

Gögelein, Heinz,

Hoechst-Marion-Roussel,
Cardiovascular Research,
65926 Frankfurt,
Germany

Greger, R.,

Institute of Physiology,
University of Freiburg,
79104 Freiburg,
Germany

Herling, Andreas W.,

Hoechst-Marion-Roussel,
Metabolism Research,
65926 Frankfurt,
Germany

Hock, Franz Jakob,

Hoechst-Marion-Roussel,
General Pharmacology,
65926 Frankfurt,
Germany

Hropot, Max,

Hoechst-Marion-Roussel,
Cardiovascular Research,
65926 Frankfurt,
Germany

Huger, Francis P.,

Hoechst-Marion-Roussel,
Neuroscience Research,
Sommerville,
NJ,
USA

Jablonka, Bernd,

Hoechst-Marion-Roussel,
Cardiovascular Research,
65926 Frankfurt,
Germany

Just, Melitta,

Hoechst-Marion-Roussel,
Cardiovascular Research,
65926 Frankfurt,
Germany

Linz, Wolfgang,

Hoechst-Marion-Roussel,
Cardiovascular Research,
65926 Frankfurt,
Germany

Maas, Jochen,

Hoechst-Marion-Roussel,
Preclinical Development,
65926 Frankfurt,
Germany

McGaugh, James L.,

University of California at Irvine,
Irvine,
CA 92717,
USA

Müller, Günter,

Hoechst-Marion-Roussel,
Metabolism Research,
65926 Frankfurt,
Germany

Raiss, Ruth X.,

Hoechst-Marion-Roussel,
Osteoarthritis Research,
65174 Wiesbaden,
Germany

v. Rechenberg, Wolfrad,
Hoechst-Marion-Roussel,
Metabolism Research,
65926 Frankfurt,
Germany

Rudolphi, Karl A.,
Hoechst-Marion-Roussel,
Cardiovascular Research,
65926 Frankfurt,
Germany

Schölkens, Bernward A.,
Hoechst-Marion-Roussel,
Cardiovascular Research,
65926 Frankfurt,
Germany

Seeger, Karl,
Hoechst-Marion-Roussel,
Pharma Research,
65926 Frankfurt,
Germany

Weithmann, K.U.,
Hoechst-Marion-Roussel,
Immunopharmacology,
65174 Wiesbaden,
Germany

Wirth, Klaus J.,
Hoechst-Marion-Roussel,
Cardiovascular Research,
65926 Frankfurt,
Germany